

REVIEW

Open Access



Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma

Jingjing Pu^{1,5†}, Ting Liu^{2†}, Amit Sharma¹, Liping Jiang³, Feng Wei⁴, Xiubao Ren^{4*}, Ingo G. H. Schmidt-Wolf^{1*} and Jian Hou^{5*}

Abstract

The basic idea of modulating the immune system to better recognize and fight tumor cells has led to the successful introduction of adoptive cellular immunotherapy (ACT). ACT-based treatment regimens, in which the patient's own immune cells are isolated and subsequently expanded (ex vivo) and reinfused, have also contributed significantly to the development of a personalized treatment strategy. Complementing this, the unprecedented advances in ACTs as chimeric antigen receptor (CAR)-T cell therapies and their derivatives such as CAR-NK, CAR-macrophages, CAR- $\gamma\delta$ T and CAR-NKT have further maximized the therapeutic outcomes. Herein, we provide a comprehensive overview of the development of ACTs in multiple myeloma (MM) and outline how they have evolved from an experimental form to a mainstay of standard clinical settings. Besides, we provide insights into cytokine-induced killer cell (CIK) therapy, an alternative form of ACT that (as CIK or CAR-CIK) has enormous potential in the clinical spectrum of MM. We also summarize the results of the major preclinical and clinical studies of adoptive cell therapy in MM and address the current challenges (such as cytokine release syndrome (CRS) and neurotoxicity) that limit its complete success in the cancer landscape.

Keywords Multiple myeloma, Cell therapy, Immunotherapy, CAR-T, CAR-NK, CIK

Introduction

Multiple myeloma (MM) is a malignancy of plasma cells in the bone marrow, comprising around 10% of all hematologic cancers. This disorder arises from the genetic alteration of stem cells, which causes normal B lymphocytes to morph into malignant myeloma cells. These cells produce dysfunctional M proteins, which contribute to disease progression and associated symptoms such as severe bone damage, kidney dysfunction, anemia, and elevated calcium levels [1–3] (Fig. 1A). In the U.S., MM predominantly affects older adults, typically beginning around age 69, with a prevalence rate of 7 per 100,000 people annually [4]. It often develops from conditions like monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM, found in 3% of those over 50 [5, 6]. MM is notably more prevalent among

[†]Jingjing Pu and Ting Liu contributed equally.

*Correspondence:

Xiubao Ren
renxiubao@tjmuch.com
Ingo G. H. Schmidt-Wolf
ingo.schmidt-wolf@ukbonn.de
Jian Hou
houjian@medmail.com.cn

¹ Department of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, 53127 Bonn, NRW, Germany

² Translational Biogerontology Lab, German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, NRW, Germany

³ Wuxi Maternity and Child Health Care Hospital, Wuxi School of Medicine, Jiangnan University, Wuxi 214002, Jiangsu, China

⁴ Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300070, China

⁵ Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China






Fig. 1 **A** The process of normal immune cell development versus the development of MM. In healthy bone marrow, stem cells develop into B lymphocytes which then mature into plasma cells, producing normal antibodies. In contrast, in multiple myeloma, genetic damage to stem cells leads to the formation of abnormal B lymphocytes, which evolve into myeloma cells. These cancerous cells produce an abnormal protein known as M protein, disrupting normal blood cell production and immune functions. Immunosuppressive Tumor Microenvironment (TME): The TME consists of tumor cells, stroma, and various immune cells, such as dendritic cells (DCs), T cells, NK cells, B cells, and macrophages, which often become exhausted and contribute to the immunosuppressive nature of the environment. **B** Timeline of significant milestones in CAR-T cell therapy development. Beginning with the use of adoptive transfer of tumor-infiltrating lymphocytes (ATILs) for metastatic cancer in 1993, significant milestones include the introduction of various generations of CAR constructs, such as CD3ζ (first generation) and 4-1BB-CD3ζ (second generation). Noteworthy is the FDA's approval of the first CAR-T cell therapies: Kymriah in 2017 for ALL and Yescarta for NHL, followed by approvals for multiple myeloma treatments, Abecma in 2021, and Carvykti in 2022. Additionally, the figure notes the ide-cel (bb2121) receiving breakthrough therapy designation, highlighting the ongoing innovation and regulatory endorsement in the CAR-T field. Each milestone in this timeline underscores the rapid evolution and increasing complexity of CAR-T cell therapies, showcasing both clinical and regulatory advancements that have significantly impacted cancer treatment paradigms. Figure created with BioRender.com

individuals of African descent and in industrialized areas such as the U.S., where it constitutes 1.8% of all cancer cases [7]. In 2022, there were about 34,470 new cases and 12,640 deaths due to MM in the U.S., and men are 1.5 times more likely to be affected than women. Over

the past two decades, the treatment landscape for MM has been transformed through the widespread adoption of autologous stem cell transplantation (ASCT) and the approval of innovative medications and strategies. A variety of new drugs, including histone deacetylase

inhibitors, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and other targeted therapies, have been developed. These advances have not only improved the five-year survival rate but also shifted treatment approaches towards more intricate combinations, such as triple therapy, and extended treatment durations to enhance patient outcomes. Notably, the tumor microenvironment (TME) in MM plays a crucial role in disease pathogenesis, progression, and therapeutic resistance [8, 9] (Fig. 1A). Targeting the TME offers a promising strategy to enhance treatment outcomes for MM patients. Current research aims to understand the complexities of the TME and develop new therapies to exploit its weaknesses [10]. Despite advances in these areas, MM remains incurable, with current treatments often limited by resistance and relapse. This highlights the urgent need for innovative therapeutic approaches to achieve a cure [11–16].

Over recent decades, advancements in adoptive cellular immunotherapy (ACT) have not only revolutionized the therapeutic landscape but have also progressively redefined the paradigms of clinical care for MM [17]. This review delves into the transformative journey of cell therapy in MM, tracing its origins from an experimental stratagem to its status as a cornerstone in the management of this challenging disease. Initially, the adoption of ASCT marked a significant breakthrough, enhancing survival rates and setting a new benchmark for care [18–20]. The introduction of ASCT in the late twentieth century heralded the first wave of innovations that provided a glimmer of hope against a once grim prognosis [21–23]. Building on this foundation, the emergence of chimeric antigen receptor (CAR)-T cell therapies catalyzed a seismic shift in the treatment modalities available for MM [24, 25] (Fig. 1B). Particularly, the development of CAR-T cells targeting the B cell maturation antigen (BCMA) has demonstrated remarkable efficacy in treating patients with relapsed/refractory multiple myeloma (RRMM), offering unprecedented response rates and opening new avenues for remission [26–28].

Further, this review explores the burgeoning role of alternative cell-based therapies, such as natural killer (NK) cells and T cell receptor (TCR) engineered cells [29–32]. These therapies are not merely adjuncts to existing treatments but are pivotal in addressing ongoing challenges such as antigen escape and resistance to CAR-T cell therapy [28, 33]. Moreover, we address the critical management of adverse effects, including cytokine release syndrome (CRS) and neurotoxicity [34–36], which are significant considerations in the deployment of these potent therapeutic options.

As we stand on the brink of significant advancements, this review anticipates future innovations,

including combination therapies and genetically tailored approaches designed to improve efficacy, safety, and personalized treatment outcomes. By integrating historical achievements with current research directions, we endeavor to shed light on the path toward achieving durable remissions and, ultimately, a cure for MM or RRMM. This review outlines key historical milestones and emphasizes the transformative potential of cell therapy in MM. The evolution of cell therapies, illustrated in Fig. 2 and elaborated in the text, shows great promise for MM treatment. Additionally, Table 1 and Supplementary Table 1 summarize the results from major pre-clinical and clinical adoptive cell therapy studies for MM.

Preclinical and clinical applications of adoptive cell therapies for MM

Autologous stem cell transplantation

Autologous stem cell transplantation (ASCT) remains the cornerstone of treatment for MM, especially in younger patients under 65 years old who are in good health [59]. This treatment follows a multi-phase therapeutic path that includes induction, high-dose melphalan (HDM) with ASCT, consolidation, and maintenance therapy, the combination of high-dose chemotherapy and ASCT provides the maximum therapeutic benefit in eligible MM patients by leveraging the cytotoxic effects of chemotherapy while ensuring recovery of bone marrow function through stem cell reinfusion. While ASCT itself does not directly target myeloma cells, it enables the use of more aggressive chemotherapy, leading to improved long-term outcomes [18, 60]. ASCT achieves high response rates and significantly extends both progression-free (PFS) and overall survival (OS), outperforming standard chemotherapy regimens [18, 61, 62]. Recent guidelines advocate for induction therapy with bortezomib, thalidomide, and dexamethasone (VTd) or bortezomib, lenalidomide, and dexamethasone (VRd) combined with the anti-CD38 monoclonal antibody daratumumab, followed by HDM-ASCT and lenalidomide maintenance [63]. Additionally, ongoing research suggests the early application of ASCT following induction therapy enhances outcomes [64–66]. With the introduction of new immunotherapies, including monoclonal antibodies and CAR-T cell therapy targeting MM cells, the role of ASCT may evolve, integrating these advances to improve response rates and minimize relapse [67, 68]. These newer strategies aim to reactivate the immune system, either passively or actively, providing deep and durable responses and raising the potential for their inclusion earlier in the treatment regimen [69]. For transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, HDM plus ASCT remains the standard of care recommended by international guidelines from organizations such as




Fig. 2 Cell therapies for multiple myeloma (MM). **A** Autologous stem cell transplantation, remains the cornerstone of treatment for MM; **B** T cell receptor (TCR) gene engineered cells enhance a patient's T cells by incorporating a receptor designed to target specific antigens, such as NY-ESO-1, and MAGE-A3, present on myeloma cells. These targeted antigens, derived from proteins commonly found in cancer cells, enable the modified T cells to recognize and destroy tumor cells that exhibit these antigens once reintroduced into the patient; **C** Chimeric antigen receptor (CAR) T cells, a groundbreaking advancement in MM, designed to enhance the body's immune response against malignant cells; **D** CAR-NK cells/genetically engineered NK cells, which express engineered receptors targeting one or more antigens, facilitate the activation of immune cells against MM cells; **E** Bispecific immune cell engagers (BiCEs)/Trispecific immune cell engagers (TriCEs) are a form of immunotherapy that targets cancer cells. By binding to both immune cells (NK cells or T cells) and MM cells, BiCEs or TriCEs bring these cells into close contact, enabling NK or T cells to effectively kill the MM cells; **F** Lymphokine-activated killer (LAK) cells, are a promising immunotherapy for MM, but further research and clinical trials are needed to fully explore and optimize their therapeutic potential; **G** $\gamma\delta$ T cells from tumor-infiltrating lymphocytes (TILs) and peripheral blood mononuclear cells (PBMCs), a subset of T cells with non-MHC-restricted cytotoxic activity, are notable for their ability to directly kill MM cells and modulate the immune response. This dual function can promote tumor eradication or facilitate tumor immune evasion; **H** Dendritic cell (DC) vaccination involves using autologous dendritic cells that have been loaded with peptides or tumor-derived proteins to activate cytotoxic T cell responses in MM patients. Figure created with BioRender.com

the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and European Bone Marrow Transplantation (EBMT) [12, 63,

70]. Until recently, induction therapy typically involved a three-drug regimen of a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and dexamethasone.

Table 1 Clinical studies of adoptive cell therapies for MM treatment

Type	Phase	Clinical design	Clinical response	Most common grade 3/4/5 toxicities	References
TCR gene engineered T cells	I/II (NCT01352286)	Treatment: Received NY-ESO-1-specific TCR-engineered T cells after ASCT Protocol: Twenty patients with antigen-positive MM received an average 2.4×10^9 NY-ESO-1-LAGE-1 TCR-engineered T cells for 2 days after ASCT	CR: 80%; PFS: 19.1 months	GVHD (17.4%), rash (6%), hypotension (6%)	[37]
	I (NCT02658929)	Treatment: BCMA-targeted CAR-T cell (Idecabtagene vicleucei; Bb2121) Protocol: CTX + FAMP + 150 or 450×10^6 cells/pt	ORR: 75.8%; CR: 38.7%; mPFS: 18.1 months	Neutropenia (88.7%), anemia (56.5%), infection (22.6%), CRS (6.5%), thrombocytopenia (56.5%), leukopenia (61.3%), lymphopenia (35.5%), ICANS (1.6%), second primary malignancy (3.2%)	[38]
CAR-T cells	I/II (NCT03090659)	Treatment: BCMA-targeted CAR-T cell (LCAR-B38M) Protocol: CTX + avg 0.5×10^6 cells/kg 3 split infusions	ORR: 87.8%; CR: 73%; MRD negativity: 67.6%; 5-year PFS: 21%; 5-year OS: 49.1%	Neutropenia (85.3%), thrombocytopenia (58.8%), and hepatic disorder (38.3%)	[39]
	Ib/II (NCT03548207)	Treatment: BCMA-targeted CAR-T cell (JNJ-4528) Protocol: CTX + FAMP + avg 0.75×10^6 cells/kg	ORR: 97.9%; sCR: 82.5%; 27-month PFS: 54.9%; 27-month OS: 70.4%	Neutropenia (94.8%), anemia (68%), thrombocytopenia (59.8%), leukopenia (60.8%), lymphopenia (50.5%), metabolism and nutrition disorders (18.5%), CRS (5.1%), ICANS (12.3%)	[40]
	Ib (NCT02546167)	Treatment: BCMA-targeted CAR-T cell (CAR-BCMA) Protocol: None or CTX + $1-5 \times 10^7$ or $1-5 \times 10^8$ cells/pt	ORR: 48%; CR: 8%; VGPR: 20%; PR: 20%	Leukopenia (44%), neutropenia (44%), lymphopenia (36%), CRS (32%), ICANS (12%)	[41]
	I (NCT03070327)	Treatment: BCMA-targeted CAR-T cell (MCARH171) Protocol: CTX + FAMP + 72, 137, 475 or 818×10^6 cells/pt (1 or 2 doses)	ORR: 64%	CRS (23%), ICANS (36%)	[42]
	I (NCT03455972)	Treatment: CD19-targeted CAR-T cell and BCMA-targeted CAR-T cell Protocol: anti-CD19 CAR-T cells were infused at a fixed dose of 1.0×10^7 kg body weight on day 0, followed by 2.0×10^7 /kg of anti-BCMA CAR-T cells on day 1 and 3.0×10^7 /kg of anti-BCMA CAR-T cells on day 2	ORR: 100%; sCR: 90%; CR: 10%	Neutropenia (20%), lymphopenia (100%), thrombocytopenia (70%), anemia (50%), elevated bilirubin (10%), hypotension (10%), respiratory infection (50%)	[43]
	II (ChiCTR17011272)	Treatment: CD19-targeted CAR-T cell and BCMA-targeted CAR-T cell Protocol: CTX + FAMP + humanized anti-CD19 CAR-T cells (1×10^6 cells/kg) and murine anti-BCMA CAR-T cells (1×10^6 cells/kg)	ORR: 95%; sCR: 43%; CR: 14%; VGPR: 24%; PR: 14%	Neutropenia (86%), anaemia (62%), thrombocytopenia (62%), CRS (4%)	[44]
	I/II (ChiCTR2000033567)	Treatment: Bispecific BC19 CAR-T cell targeting BCMA/CD19 Protocol: Not found	ORR: 92%; mPFS: 19.7 months; mOS: 19.7 months	Neutropenia (98%), anemia (64%), thrombocytopenia (66%), leukopenia (96%), AST increased (24%), Pyrexia (24%), CRS (8%)	[45]

Table 1 (continued)

Type	Phase	Clinical design	Clinical response	Most common grade 3/4/5 toxicities	References
	I (ChiCTR1800018143)	Treatment: Bispecific BM38 CAR-T cell targeting BCMA/CD38 Protocol: CTX + FAMP + anti BM38 CAR-T cells (0.5, 1.0, 2.0, 3.0 and 4.0 × 10 ⁶ cells/kg)	ORR: 87%; CR: 52%	CRS (22%), neutropenia (87%), anemia (13%), thrombocytopenia (47%), leukopenia (83%)	[46]
	I (ChiCTR1900026286)	Treatment: Bispecific BM38 CAR-T cell targeting BCMA/CD38 Protocol: CTX + FAMP + anti BM38 CAR-T cells	ORR: 88%; CR: 81%	Anemia (37.6%), thrombocytopenia (25%), leukopenia (93.8%), CRS (31.3%)	[47]
	I (ChiCTR1800017051)	Treatment: CD38-targeted CAR-T cell and BCMA-targeted CAR-T cell Protocol: CTX + FAMP + humanised anti-BCMA CAR-T cells (2 × 10 ⁶ cells/kg) and murine anti-CD38 CAR-T cells (2 × 10 ⁶ cells/kg)	ORR: 90.9%; CR: 54.5%	Fever (36.4%), leukopenia (36.4%), anemia (27.3%), CRS (27.3%)	[48]
	I/IIa (NCT04662099)	Treatment: Bispecific CS1 CAR-T cell targeting CS1/BCMA Protocol: CTX + FAMP + bispecific CS1-BCMA CAR-T cells (0.75 × 10 ⁶ , 1.5 × 10 ⁶ and 3.0 × 10 ⁶ cells/kg)	ORR: 81%; sCR: 38%	CRS (6%), pain (19%), infection (31%), leukopenia (100%), neutropenia (94%), lymphopenia (100%), anemia (13%), thrombocytopenia (31%)	[49]
	I (NCT04555551)	Treatment: GPRC5D-targeted CAR-T cell (MCARH109) Protocol: GPRC5D-targeted CAR-T cells (25 × 10 ⁶ to 450 × 10 ⁶ cells in total)	ORR: 71%; CR: 35%; MRD negativity: 47%	CRS (5.9%), ICANS (5.9%)	[50]
CAR-NK cells	I (NCT04674813)	Treatment: GPRC5D-targeted CAR-T cell (BMS-986393) Protocol: GPRC5D-targeted CAR-T cells (25 × 10 ⁶ to 450 × 10 ⁶ cells in total)	Patients with assessable efficacy: ORR: 86%; CR: 38%; patients refractory to prior BCMA-directed therapy: ORR: 85%; CR: 46%	Neutropenia (69%), anemia (31%), thrombocytopenia (30%), CRS (4.3%), ICANS (3%)	[51]
	I (NCT05016778)	Treatment: GPRC5D-targeted CAR-T cell (OriCAR-017) Protocol: GPRC5D-targeted CAR-T cells (1 to 6 × 10 ⁶ CAR-T cells/kg)	ORR: 100%; sCR: 60%	Neutropenia (100%), thrombocytopenia (90%), leukopenia (90%), anemia (70%)	[52]
	I/II (NCT03940833)	Treatment: BCMA-specific CAR-NK 92 cell Protocol: Not found	Not found	Not found	Not found
	I (NCT05182073)	Treatment: Allogenic CAR NK cells with BCMA expression (FT576) Protocol: CTX + FAMP + Daratumumab + Bendamustine + FT576	Not found	Not found	Not found
	I/II	Treatment: rIL-2 Protocol: 9 × 10 ⁶ IU/m ² twice daily on day 1 and 2, then 0.9 × 10 ⁶ IU/m ² twice daily from day 3 to 56, every 12 weeks until disease progression	ORR: 35.3%	Not found	[53]
LAK cells					

Table 1 (continued)

Type	Phase	Clinical design	Clinical response	Most common grade 3/4/5 toxicities	References
γδ T cells	I	Treatment: rIL-2 Protocol: 0.3 to 4.5 × 10 ⁶ IU/m ² daily, from day 1 to 5, then 0.3 × 10 ⁶ IU/m ² daily from day 12 to 21	Not found	Most patients exhibited mild to moderate fever, nausea, diarrhea, and/or skin rash	[54]
	II	Treatment: Zoledronate + IL-2 Protocol: IL-2: 2 × 10 ⁶ –8 × 10 ⁶ IU/day (increased by 25% each time until toxicity was observed); 4 mg of zoledronic acid were administered on day 2 of each cycle	CR: 18%	Treatment was well tolerated without G3 or 4 toxicities	[55]
	I	Treatment: Pamidronate + IL-2 Protocol: Pamidronate on day 1 followed by increasing dose levels of IL-2 from day 3 to day 8 (0.25–3 × 10 ⁶ IU/m ²); pamidronate on day 1, followed directly by IL-2 administration from day 1 to day 6	PR: 33%	Thrombosis (10%)	[56]
	I	Treatment: Zoledronate + IL-2 activated allogeneic γδ T cells from healthy donors Protocol: On average, patients received 2.17 × 10 ⁶ /kg (range 0.9–3.48) γδ T cells. All patients received prior lymphopenia-inducing chemotherapy (FAM 20–25 mg/m ² day -6 until day -2 and CTX 30–60 mg/kg day -6 and -5) and were treated with 4 mg zoledronate on day 0 and 1.0 × 10 ⁶ IU/m ² IL-2 on day +1 until day +6 for the induction of γδ T cell proliferation in vivo	CR: 75% (patients with plasma cell leukemia)	Neutropenia (100%)	[57]
DC vaccination	I (NCT04688853)	Treatment: TEG002 cells (autologous T cells transduced with a specific γδTCR) Protocol: Not found	Ongoing	Not found	Not found
	II (NCT02728102)	Treatment: DC/MM fusion vaccine + lenalidomide (Revlimid) + GM-CSF Protocol: DC/MM fusion vaccine was given on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance therapy, starting 90–100 days after auto-HSCT, and continued for 2 years. GM-CSF was given daily for a total of 4 days of each cycle (each cycle lasted 28 days)	CR: Vaccine group vs control group (52.9% vs 50%); VGPR: Vaccine group vs control group (85.3% vs 77.8%)	Blood and lymphatic disorders (52.9%), gastrointestinal disease disorders (14.7%), nervous system disorders (16.2%), metabolism and nutrition disorders (10.3%)	[58]

MM: multiple myeloma; ORR: overall response rate; sCR: stringent complete response; MPD: minimal residual disease; CR: complete responses; VGPR: very good partial response; PR: partial response; OS: overall survival; mOS: median overall survival; PFS: progression-free; mPFS: median progression-free; GVHD: Graft Versus Host Disease; CRS: cytokine release syndrome; ICANS: immune effector cell-associated neurotoxicity syndrome; CTX: cyclophosphamide; FAM: fludarabine; pt: per test; data sourced from the clinicaltrials.gov site and the chict.org.cn site

However, the treatment landscape has shifted with the introduction of anti-CD38 monoclonal antibodies, daratumumab and isatuximab, leading to the adoption of four-drug regimens (quadruplets) in place of the previous three-drug regimens (triplets) [71, 72].

Induction regimens for ASCT

Daratumumab, a human IgG/kappa monoclonal antibody targeting CD38, is approved for treating RRMM and NDMM [73–76]. It has become a new standard of care in transplant-eligible NDMM, as shown in the phase III CASSIOPEIA trial (NCT02541383), where adding daratumumab to VTd improved stringent complete response (sCR) rates and PFS, with 64% achieving minimal residual disease (MRD) negativity [77, 78]. The phase II GRIFIN study (NCT02874742) further demonstrated the efficacy of daratumumab with VR, showing higher sCR and MRD negativity rates than VRd alone [79, 80]. These findings were confirmed by the phase III PERSEUS study (NCT03710603), where daratumumab plus VRd significantly improved PFS and MRD negativity rates [81]. Additionally, the phase II MASTER trial (NCT03224507) highlighted the potential of MRD-driven therapy adjustments with the Dara-KRd regimen (daratumumab, carfilzomib, lenalidomide, dexamethasone), offering a treatment-free state for MRD-negative patients [82]. These studies collectively affirm the benefits of incorporating daratumumab into standard treatment regimens for NDMM.

Isatuximab, a chimeric IgG monoclonal antibody targeting a unique epitope on CD38, exerts anti-myeloma effects through mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, direct induction of apoptosis, and inhibition of CD38 enzyme activity [83, 84]. Approved for RRMM, it is also being explored for NDMM in transplant-eligible patients [85–88]. In the phase III GMMG-HD7 trial (NCT03617731), 660 transplant-eligible NDMM patients received either isatuximab plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd) or standard VRd. The trial reported a 50% MRD negativity rate in the isatuximab group compared to 36% in the control group ($p=0.00017$) [89]. The phase II GMMG-CONCEPT trial (NCT03104842) evaluated isatuximab with carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in high-risk NDMM patients. Post-consolidation, 72.8% achieved complete or stringent complete responses, 18.2% very good partial responses, and an overall response rate of 94.9%. MRD negativity was achieved by 67.7% after consolidation and 81.8% at some point. Sustained MRD negativity for 6 and 12 months was 72.7% and 62.6%, respectively. With a median follow-up of

44 months, the median PFS had not been reached, highlighting Isa-KRd's potential in high-risk NDMM [90].

Advancements in stem cell mobilization and collection techniques

Mobilizing CD34⁺ stem cells from bone marrow to peripheral blood is essential for harvesting adequate hematopoietic stem cells (HSC) for ASCT. A minimum of $2 \times 10^6/\text{kg}$ CD34⁺ cells is required, with optimal targets of $>3 \times 10^6/\text{kg}$ for one ASCT and $>6 \times 10^6/\text{kg}$ for two ASCTs. While the optimal mobilization strategy remains debated, current methods include granulocyte colony-stimulating factor (G-CSF), optionally preceded by Cyclophosphamide ($1.5\text{--}4 \text{ g/m}^2$) [91–93]. Plerixafor, a selective CXCR4 antagonist, enhances mobilization by preventing HSC adherence to the marrow, reducing procedure failure, and minimizing adverse events like neutropenia [94–96]. Anti-CD38 monoclonal antibodies used in induction therapy for NDMM have shown reduced HSC mobilization efficiency, as seen in the CASSIOPEIA trial, which reported lower CD34⁺ cell yields with the D-VTd regimen compared to VTd (6.7 vs. $10.0 \times 10^6/\text{kg}$), higher plerixafor use (21.7% vs. 7.9%), and increased collection failures (24.6% vs. 11.4%) [97–99]. The MASTER and GRIFFIN trials also indicated high plerixafor use with daratumumab-containing regimens but found no negative impact on ASCT feasibility or safety [100]. Another study on 179 NDMM patients from the GMMG-HD6 and GMMG-HD7 trials (NCT02495922, NCT03617731) showed successful mobilization ($>6 \times 10^6/\text{kg}$ CD34⁺ cells) with VRd, I-VRd, and elotuzumab-VRd, confirming that isatuximab addition does not negatively affect mobilization [101–103]. These findings underscore that despite varying yields and increased plerixafor use, integrating daratumumab or isatuximab into induction regimens does not hinder successful stem cell collection or ASCT outcomes.

T cell receptor (TCR) gene engineered T cells

The TCR is essential for the specific activation and clonal expansion of T cells in response to antigens. TCRs are generally heterodimers, composed of α and β chains, each featuring constant and variable domains. The variable domain undergoes somatic recombination, creating a vast diversity of TCR clonotypes, essential for recognizing antigens presented on cells by major histocompatibility complex (MHC) molecules [104, 105]. Unlike CARs, TCRs lack an intrinsic signaling domain and require the CD3 complex to transmit activation signals through phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs). This interaction initiates various signaling pathways, leading to T cell activation [106, 107]. TCRs are highly sensitive; a few interactions

with peptide-MHC (pMHC) complexes can trigger T cell responses, including cytokine production and target cell killing. High avidity TCRs, which bind strongly to pMHC, typically induce stronger immune responses and are more effective at lower antigen concentrations [108, 109]. However, T cells with lower-affinity TCRs are also crucial, maintaining immune effectiveness across a range of conditions and contributing to long-term immune memory, especially in chronic infections and cancer [110, 111]. Co-stimulation is necessary for optimal TCR signaling, provided by interactions with co-receptors and ligands that modulate T cell responses. This modulation influences T cell differentiation, proliferation, and longevity, which are key for effective immune responses and potential therapeutic interventions [109, 112, 113]. Understanding the integration of these signals can enhance T cell-based therapies by adjusting co-stimulation to improve T cell functionality in diverse disease settings.

TCR therapy for MM involves engineering patient T cells to target specific antigens such as NY-ESO-1 [37, 114], MAGE-A3 [115, 116], and BCMA [117], which are either unique to or overexpressed by MM cells. This strategy enables the modified T cells, upon reintroduction into the patient, to specifically identify and eradicate malignant cells. The effectiveness of this therapeutic approach largely depends on the selection of appropriate target antigens [67]. NY-ESO-1 is often selected due to its restricted expression in normal tissues, enhancing its safety profile [118, 119]. MAGE-A3 is chosen for its tumor-specific expression, providing a high degree of cancer selectivity [120, 121]. Additionally, BCMA, a target commonly utilized in CAR-T cell therapies [27, 122, 123], is increasingly being considered for TCR-based strategies due to its prevalent expression in MM cells [124]. However, BCMA itself, as a protein expressed on the surface of B cells, is not typically a target for TCR therapies because TCRs recognize peptides presented by MHC molecules on the surface of cells, rather than whole proteins or antigens directly exposed on the cell surface. This precision in antigen targeting is crucial for the success of TCR therapies in treating MM.

TCR-engineered T cells targeting NY-ESO-1 tumor antigen

NY-ESO-1, a cancer-testis antigen, is primarily expressed in a variety of cancers but is absent in normal tissues with the exception of the testis. The testis lacks expression of the MHC, enabling evasion of immune detection. The restricted expression and immunogenic properties of NY-ESO-1 render it an ideal target for cancer immunotherapy [125–127]. In the context of oncological research, NY-ESO-1 mRNA has been identified in 20–40% of tumors, including those of the esophageal,

gastric, melanoma, prostate, and several other carcinomas [128–131]. Its expression is notably associated with advanced cancer stages and correlates with poorer survival outcomes, emphasizing its potential as a prognostic marker. This antigen's relevance is particularly pronounced in MM, where NY-ESO-1 expression is predominantly observed in advanced stages of the disease [132]. The progression from diagnosis to relapse often sees an increase in NY-ESO-1 levels, mirroring broader malignancy trends where progression correlates with the upregulation of cancer/testis antigen (CTA) genes such as NY-ESO-1. This upregulation is likely a consequence of global hypomethylation events within the genome [133]. Mastaglio et al. demonstrated that single TCR gene editing using the clinical-grade HLA-A2 restricted NY-ESO-1157-165-specific TCR can quickly generate large quantities of tumor-specific T cells. These cells effectively target and eliminate cancer cells, showing a strong and safe performance compared to traditional TCR-transferred cells. The edited cells also have a better safety profile, minimizing risks like graft-versus-host disease in mice models. This approach offers a promising and safer method for advancing cancer immunotherapy treatments [118]. Moreover, Rapoport et al. conducted a study (NCT01352286) on 20 MM patients using engineered T cells targeted at cancer antigens NY-ESO-1 and LAGE-1. The treatment was well-tolerated, with no severe side effects, and the T cells showed effective targeting and persistence in the marrow. The presence of these T cells correlated with better clinical outcomes, leading to promising responses in 80% of the patients, with a median PFS of 19.1 months [37]. These studies confirmed that these engineered T cells are safe and effective for treating MM.

TCR-engineered T cells targeting MAGE-A3 tumor antigen

MAGE-A3 is a member of the melanoma antigen gene (MAGE) family, which are typically not expressed in normal tissues except in testicular germ cells but are expressed in various types of cancers, including melanoma, non-small cell lung cancer, and others. This makes MAGE-A3 an attractive target for cancer immunotherapy [134–136]. Jungbluth et al. showed that MAGE-A3 serves as a promising antigen associated with myeloma, potentially valuable for vaccine-based immunotherapy. Additionally, the widespread expression and its association with cellular proliferation imply a pathogenic role for this gene in MM development [121]. Atanackovic et al. demonstrated that MAGE-A3 significantly enhances the survival of myeloma cells and their clonogenic precursors by diminishing the rates of both spontaneous and chemotherapy-induced apoptosis. Consequently, MAGE-A3 may serve as a promising target for the development of novel, myeloma-specific therapeutic strategies

[120]. However, Linette et al. reported two patients with MAGE-A3-positive tumors received T cells modified to target an HLA-A*01-restricted peptide but died within a week from severe myocardial damage caused by an off-target reaction. Autopsies revealed no MAGE-A3 in the heart, but studies showed the T cells reacted to an unrelated cardiac peptide (NCT01350401 and NCT01352286) [137]. This highlights the risks of off-target effects with enhanced TCRs, emphasizing the need for careful analysis and early intervention in TCR-based therapies.

Chimeric antigen receptor (CAR) T cells

CARs are genetically engineered receptors designed to recognize specific antigens, and are expressed on the surface of immune cells (Fig. 3B). The extracellular domain of a CAR typically consists of a single-chain variable fragment (scFv) that binds to antigens overexpressed on tumor cells. This scFv is connected via a hinge domain (e.g., CD8, CD28, IgG1, or IgG4) to a transmembrane domain (e.g., CD28, 4-1BB, or CD8). Intracellularly, CARs include one or more costimulatory domains (e.g., CD28, 4-1BB, or OX40, absent in first-generation CARs) and a CD3 ζ activation domain [138, 139] (Fig. 3A). This configuration enables full T-cell activation upon antigen recognition. CAR-T cell therapy has significantly advanced cancer immunotherapy, demonstrating substantial efficacy in treating hematological malignancies, including MM [28, 140, 141].

BCMA targeted CAR-T cells

BCMA, or B-cell maturation antigen is crucial in MM pathogenesis, largely due to its interactions with the ligands APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor) [142–144]. These interactions support the survival and proliferation of MM cells [145]. BCMA is mainly found on plasma cells, which are central to MM, and is significantly overexpressed in myeloma cells compared to normal ones [122, 146]. Upon binding with APRIL and BAFF, BCMA triggers various signaling pathways, notably the NF- κ B pathway, enhancing gene transcription that supports cell survival, growth, and chemotherapy resistance [147, 148]. This relationship also modifies the bone marrow environment, further facilitating myeloma cell growth. Given its specific overexpression in myeloma cells and limited presence in normal cells, BCMA is an effective target for therapies like antibody–drug conjugates, bispecific T-cell engagers (TCEs), and CAR-T cell therapies [27, 67, 149, 150]. These treatments focus on selectively eliminating myeloma cells with minimal impact on healthy cells.

In the preclinical phase, BCMA targeted CAR-T cells demonstrated potent cytotoxic activity *in vitro* and *in vivo* against myeloma cells. These studies often involve

testing the CAR-T cells against human myeloma cell lines in mice models to observe the efficacy and safety of the treatment [151–156]. Safety is a critical aspect of pre-clinical trials. CAR-T cell therapy can lead to CRS and neurotoxicity, which are significant concerns [157, 158]. Preclinical models have been used to study these effects and refine the cell manufacturing process and dosing strategies to minimize adverse effects. Moreover, further advancements in CAR-T cell designs are ongoing in pre-clinical studies to enhance their effectiveness and reduce side effects. This includes modifications like the inclusion of suicide genes [159], dual-targeting CARs [160], or using different co-stimulatory domains to improve cell persistence and function [161, 162]. These preclinical findings are foundational for advancing BCMA targeted CAR-T therapy into clinical settings, where the real-world efficacy and safety can be evaluated in patients with MM. This research is crucial in potentially offering a new and effective treatment for patients who have RRMM.

In the clinical phase, Idecabtagene vicleucel (Abecma), also known as Bb2121, is the first CAR-T cell therapy approved by the U.S. Food and Drug Administration (FDA) for adults with RRMM in March 2021. This therapy targets patients whose MM has either recurred or failed to respond to prior treatments [163]. Lin et al. conducted a phase I multicenter study (CRB-401) on 62 patients with RRMM, followed for a median of 18.1 months. The study (NCT02658929) primarily assessed safety and showed low rates of serious side effects, with 6.5% experiencing severe CRS and 1.6% severe neurotoxicity. The overall response rate (ORR) was 75.8%, with 64.5% achieving a very good partial response (VGPR) or better, and 38.7% reaching CR or sCR. Secondary measures included median durations of CR, PFS, and OS at 10.3, 8.8, and 34.2 months, respectively. Furthermore, the expansion of Bb2121 in blood and bone marrow was linked to clinical effectiveness and a decrease in soluble BCMA. Notably, patients with longer PFS (≥ 18 months) had T cells that were less exhausted and showed a more robust functional phenotype [38]. These findings support the safety, tolerability, and effectiveness of Bb2121, highlighting specific T cell characteristics associated with durable responses. LCAR-B38M (JNJ-68284528) is a second-generation, bispecific CAR-T cell therapy targeting two distinct BCMA epitopes, enhancing its binding affinity. This differentiates it from other BCMA-directed CAR-T therapies. The therapy is being evaluated in the LEGEND-2 phase I/II trial (NCT03090659) in China for patients with RRMM. The study reported a 5-year PFS of 21.0% and OS of 49.1%, noting a stabilization of survival curves over time. Participants achieving CR demonstrated notably higher

5-year PFS and OS rates of 28.4% and 65.7%, respectively. Notably, 12 patients (16.2%) maintained relapse-free status despite high-risk cytogenetic abnormalities and all had restored normal humoral immunity. A sustained CR was associated with favorable prognostic factors including good performance status, IgG subtype, absence of extramedullary disease, and a lymphodepletion regimen combining cyclophosphamide (CTX) and fludarabine (FAM). Among the patients, 83.8% experienced disease progression or death; however, 61.1% of those responded to subsequent therapies, particularly proteasome inhibitor-based treatments. Safety profiles showed comparable recovery of hematologic and hepatic functions across groups, with a low incidence of secondary malignancies (5.4%) and no severe viral infections. One patient in persistent remission exhibited a sustainable CAR-T population characterized by a predominance of indolent, low-cytotoxicity CD4/CD8 double-negative T cells [39]. The CARTITUDE-1 phase Ib/II study (NCT03548207) evaluated ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma, demonstrating sustained, profound responses after 12 months. Updated results, with a median follow-up of 27.7 months (N=97), show a remarkable ORR of 97.9% and a sCR rate of 82.5%. Patients, including high-risk subgroups, received a single cilta-cel infusion following lymphodepletion. Median PFS and OS were not reached, with 27-month PFS and OS rates at 54.9% and 70.4%, respectively. Response durations were reduced in high-risk patients. The treatment's safety profile remained manageable, with stable adverse events. These findings, at around 28 months, confirm cilta-cel's robust efficacy and favorable risk/benefit ratio in treating advanced MM [40]. In a phase Ib study (NCT02546167), Cohen et al. evaluated autologous T cells modified with a lentiviral BCMA-specific CAR, incorporating CART-BCMA, in 25 patients with RRMM. Participants were assigned to three cohorts: 1) $1-5 \times 10^8$ CART-BCMA cells, 2) $1-5 \times 10^7$ CART-BCMA cells plus CTX at 1.5 g/m^2 , and 3) $1-5 \times 10^8$ CART-BCMA cells plus CTX at the same dose. BCMA expression was not a criterion for inclusion. All patients received the engineered T cells, which expanded successfully. Significant adverse effects were CRS and neurotoxicity, observed as grade 3–4 in 32% and 12% of patients, respectively, but these were reversible. One death occurred due to candidemia and advancing MM on day 24 after severe complications. Therapeutic responses varied across cohorts, with efficacy rates of 44% in cohort 1, 20% in cohort 2, and 64% in cohort 3. Outcomes included five partial, five very good partial, and two complete responses. Three responses were maintained for up to 32 months. Response and T cell expansion correlated with the CD4:CD8 ratio and CD45RO⁺CD27⁺CD8⁺

T cell prevalence in the pre-treatment leukapheresis product. CART-BCMA treatment, with or without lymphodepleting chemotherapy, showed clinical activity in extensively treated MM patients [41]. The phase I dose-escalation trial (NCT03070327) assessed MCARH171 in RRMM patients. Participants underwent a FAMP and CTX conditioning regimen before receiving 1–2 doses of MCARH171. Four escalating doses tested range from 72×10^6 to 818×10^6 CAR-T cells. As of July 16, 2018, 11 patients, having previously failed an average of six myeloma treatments, were treated, achieving an ORR of 64% with a median duration of response (mDOR) of 106 days. Patients in high-dose cohorts exhibited greater peak expansion, prolonged persistence of MCARH171, and more sustained clinical responses compared to those in low-dose cohorts. CRS was reported in six patients, with two experiencing grade 3 severity. Additionally, one patient developed transient grade 2 encephalopathy that resolved within 24 h. No dose-limiting toxicities (DLTs) were observed [42]. CART-BCMA therapies, have demonstrated significant efficacy in RRMM, though they are associated with severe neurological toxicities, primarily immune effector cell-associated neurotoxicity syndrome (ICANS). ICANS typically occurs within the first week of treatment and presents with a range of symptoms, including headache, confusion, delirium, aphasia, tremors, and seizures. In more severe cases, it can progress to encephalopathy, coma, or cerebral edema, which may be fatal. Motor dysfunction, such as tremors and muscle weakness, and seizures have also been reported. While ICANS often occurs alongside CRS, it can manifest independently. Prompt recognition and management of these neurotoxic effects, typically with corticosteroids or other immunosuppressive agents, are critical to preventing life-threatening complications [164]. Despite these risks, studies consistently highlight the potential of BCMA-targeted CAR-T therapies in advanced MM, demonstrating both robust efficacy and a manageable safety profile across diverse patient cohorts.

CD19 targeted CAR-T cells

CD19 is typically not targeted in MM treatments because it is mainly found on B cells and their precursors, while MM primarily arises from plasma cells, which do not usually express CD19 [165–168]. Consequently, CD19-targeted CAR-T cell therapy, effective in other B-cell malignancies, has limited applicability in MM [169, 170]. However, emerging research indicates that a small subset of MM cells might express CD19 or that combining CD19 with other antigens could enhance treatment efficacy [28]. The infusion of anti-CD19 and anti-BCMA CAR-T cells in patients with NDMM or RRMM has shown promising results and manageable side effects




Fig. 3 **A** Structure of different CAR generations. The core structure of a CAR is delineated by its primary components: the extracellular domain, the transmembrane domain, and the intracellular domain. The development of CAR-T cells has evolved significantly across generations. First-generation CARs featured only a signaling domain in the intracellular region. This was followed by second-generation CARs, which incorporated one co-stimulatory molecule. Third-generation CARs included an additional co-stimulatory molecule, enhancing their efficacy. Fourth-generation CARs, also known as TRUCKs (T cells redirected for universal cytokine-mediated killing), are based on second-generation designs but also express cytokines like IL-12 either constitutively or inducibly. The latest, fifth generation, builds further on the second-generation framework by adding intracellular domains of cytokine receptors, such as the IL-2Rβ chain fragment, which includes a STAT3/5 binding motif, to enhance signaling and T cell activity. **B** CARs can be engineered to be expressed on various immune cells, including T cells, NK cells, and macrophages, enabling these cells to recognize specific tumor antigens without reliance on MHC presentation. This overview encapsulates the array of molecules currently under investigation as potential CAR targets in MM. These include BCMA, CD19, CD38, CD138, SLAMF7, GPRC5D, FcRH5, NKG2D, k light chain, NY-ESO-1, CD44V6, CD46, CD56, CD70, CD74, CD229, integrin β7, ILT3, MUC1, CCR10, Lewis Y antigen and SEMA4A. Figure created with BioRender.com

[43, 44], despite not conclusively preventing progression post-anti-BCMA therapy. There are indications of its potential benefit, particularly in dual-targeted strategies. For instance, early studies have begun to explore dual-targeting CAR-T cells aimed at both BCMA and CD19, though these are less prevalent than BCMA-focused therapies [171]. A recent Phase I/II trial in China (ChiCTR2000033567) investigating a BCMA-CD19 bispecific CAR-T cell therapy showed that BC19 CAR T cells are feasible, safe, and effective for treating patients with RRMM, demonstrating promising early responses [45].

CD38 targeted CAR-T cells

CD38, a glycoprotein found abundantly on the surface of MM cells, serves as an ideal target for therapeutic interventions, such as monoclonal antibodies (daratumumab and isatuximab) [83, 172–174]. This molecule is integral to various cellular processes including cell adhesion, signal transduction, calcium signaling, and the regulation of apoptosis—a key mechanism in cancer treatment [175, 176]. Its high and uniform expression on plasma cells and other lymphoid cells highlights its potential as a focal point for novel therapeutic strategies in MM [177, 178]. Several research groups have developed anti-CD38 CAR-T cells and tested them in preclinical studies [179–182]. These cells often lack CD38 expression, likely due to the elimination of CD38-positive cells among them, a process known as fratricide. Despite this, the anti-CD38 CAR-T cells effectively target myeloma cells, supporting previous findings that CD38 is not essential for T cell functionality [183]. Notably, Glisovic-Aplenc et al. reported the anti-CD38 CAR-T cells they produced did not experience fratricide, potentially because of a protective mechanism within the CAR construct. These CAR-T cells can deplete CD34⁺ CD38⁺ hematopoietic progenitors in vitro and in vivo; however, they appear to spare other hematopoietic lineages, indicating that the CD34⁺CD38[−] low/negative cells can sustain hematopoiesis [180, 182]. As these therapies progress to clinical trials, it is crucial to monitor their impact on the immune and hematopoietic systems in patients.

In the clinical phase, Mei et al. developed a CAR-T cell with dual targeting domains for CD38 and BCMA, and a 4-1BB co-stimulatory domain, selecting a scFv with lower CD38 affinity to minimize hematopoietic toxicity (ChiCTR1800018143) [46]. This construct was administered to 23 patients, resulting in an ORR of 87%, with 52% achieving CR. Common toxicities included CRS in 87% of patients and significant cytopenias in 96%, with severe cases (grade ≥ 3) in 17% and 87% respectively. Two fatalities occurred due to infection and cerebral hemorrhage. The duration of response (DOR) reached 76%

over one year. Another study with a similar dual-targeted CAR-T cell construct reported on 16 RRMM patients, showing comparable toxicities and an ORR of 88% with 81% CR. Notably, one patient died from an infection during prolonged CRS and persistent cytopenias related to hemophagocytic lymphohistiocytosis [47]. Moreover, Zhang et al. administered separate anti-CD38 and anti-BCMA CAR-T cells to 22 patients, achieving an ORR of 91% and CR rate of 55%. However, two deaths occurred due to CRS [48]. In summary, the primary challenge in analyzing these studies is determining the specific toxicity and responses caused by the anti-CD38 therapy component, as it was always used in combination with anti-BCMA constructs.

SLAMF7 targeted CAR-T cells

The glycoprotein cell surface receptor signaling lymphocytic activation molecule family member 7 (SLAMF7), also known as CD319 or CS1, is a receptor found primarily on MM cells, natural killer cells, and some T cell subsets [184, 185]. Its high expression on malignant plasma cells and crucial role in plasma cell survival has led to the development of targeted therapies [186]. One such therapy, the anti-SLAMF7 antibody elotuzumab, has been FDA-approved for use with lenalidomide and dexamethasone in treating RRMM [187]. Additionally, using CAR-T cells to target SLAMF7 offers a promising approach to treat MM.

Several groups have developed anti-SLAMF7 CAR-T cells, showing promise in preclinical models for treating MM. Gogishvili et al. engineered CAR T cells with elotuzumab's target-binding domain and a CD28 co-stimulatory domain, effectively targeting myeloma in patient-derived and murine models [188]. Although SLAMF7 is also present on various immune cells, leading to potential fratricide, post-manufacture CAR T cells mostly lacked SLAMF7 expression, mitigating this issue. They also spared SLAMF7-low immune cells while depleting high expressers. Furthermore, Roders et al. enhanced anti-myeloma efficacy by using CRISPR/Cas9 to eliminate CD38 in T cells, creating a dual CAR system targeting CD38 and SLAMF7 [189]. This approach showed robust responses without the toxicity seen in anti-CD38 CAR T therapy, suggesting a safer alternative. O'Neal et al. utilized a different SLAMF7-binding epitope and a third-generation co-stimulatory domain, producing mainly CD4⁺ CAR-T cells due to CD8⁺ T cell fratricide [190]. They further applied CRISPR/Cas9 to prevent fratricide, achieving a balanced CD4/CD8 ratio without enhancing efficacy significantly. Collectively, these studies indicate the potential of anti-SLAMF7 CAR-T cells in myeloma treatment, though the implications of fratricide require more research. In a phase I/

IIa clinical trial initiated based on preclinical studies of a dual-targeted single-chain CAR featuring anti-BCMA and anti-SLAMF7 domains, results from 16 treated patients were recently published [49]. The trial reported toxicities including CRS in 38% of cases, 6% of which were grade 3 or higher, but no instances of Immune effector cell-associated neurotoxicity syndrome (ICANS). All patients experienced cytopenias, with 100% encountering severe (grade ≥ 3) cases. Infections occurred in 38% of the patients, with severe infections (grade ≥ 3) in 31%. Efficacy was notable, with an ORR of 81% and sCR rate of 38%.

GPRC5D targeted CAR-T cells

G protein-coupled receptor class C group 5 member D (GPRC5D) is a protein predominantly expressed on the surface of MM cells but with limited expression in normal tissues [191–193]. This makes it an attractive target for CAR-T therapy because therapies directed against it can potentially kill myeloma cells while sparing most healthy cells [194]. In murine and nonhuman primate models, CAR-T cells targeting GPRC5D showed effective anti-MM activity in vivo, including in BCMA escape models, without on-target, off-tumor toxicity [195, 196]. This success has spurred the clinical development of therapeutic agents that target GPRC5D for MM treatment. In a 2022 phase I study by Mailankody et al. [50], 17 RRMM patients, all previously treated with at least three lines of therapy including proteasome inhibitors (PIs), IMiDs, anti-CD38, and BCMA-targeted therapies, received infusions of MCARH109. This CAR-T cell therapy features a humanized anti-GPRC5D scFv target-binding domain and a 4-1BB co-stimulatory domain. Doses ranged from 25 to 450×10^6 CAR T-cells. The study established 150×10^6 CAR-T cells as the maximum tolerated dose after observing severe adverse events, including grade 4 CRS and ICANS in one patient, and grade 3 cerebellar disorder in two patients at the highest dose level. These neurological effects were likely due to low-level, off-target GPRC5D expression. Among patients who received 25 to 150×10^6 CAR-T cells, no severe CRS or neurotoxicity was reported, and ORR was 71%, with 58% for those administered up to the maximum tolerated dose. Other mild side effects included grade 1 nail changes in 65% of patients and grade 1 taste alterations or dry mouth in 12%. Moreover, BMS-986393 is an autologous CAR-T cell therapy targeting GPRC5D, evaluated in a phase I, first-in-human trial (CC-95266-MM-001, NCT04674813) [51]. This multi-center study involved patients with three or more prior lines of therapy, including PIs, IMiDs, anti-CD38 therapy, and ASCT, alongside previous BCMA-targeted therapies. In the dose expansion cohort of 70 patients, BMS-986393 doses ranged

from 25 to 450×10^6 CAR-T cells. Of these patients, 46% had prior BCMA-targeted therapy, and 36% had prior BCMA-directed CAR-T cell therapy. The ORR was 86%, with a 38% CR rate in patients with assessable efficacy, and 85% ORR with a 46% CR in those refractory to prior BCMA-targeted therapies. Common severe side effects included neutropenia (69%), anemia (31%), and thrombocytopenia (30%). There were no severe adverse events related to skin, nails, or taste. CRS occurred in 84% of patients, mostly mild; however, severe CRS led to one death and affected three additional patients. Neurological toxicities were noted, with 11% experiencing ICANS, and other neurological symptoms like cerebellar toxicity and headache occurring in a few patients. This data supports the potential of BMS-986393 as a treatment for RRMM, with further investigations ongoing. Furthermore, OriCAR-017, another GPRC5D-targeted autologous CAR T-cell therapy, features the proprietary Ori signal activation domain to enhance memory immune cells' expansion efficiency, boosting the anti-tumor effectiveness and longevity of CAR T-cells in vivo [191]. In the phase I POLARIS trial in China (NCT05016778) [52], 10 RRMM patients received OriCAR-017 in doses from 1 to 6×10^6 CAR-T cells/kg. All patients experienced hematologic toxicities, such as neutropenia (100%), thrombocytopenia (90%), leukopenia (90%), and anemia (70%). Ninety percent encountered grade 1 CRS, 10% had grade 2 CRS, and there were no cases of neurologic toxicities. ORR was 100%, with 60% achieving sCR. After a median follow-up of 7.8 months, disease progression occurred in two patients. However, mechanisms underlying resistance to anti-GPRC5D CAR-T cell therapy are becoming clearer. Mailankody et al. showed that unlike relapse after anti-BCMA CAR-T cell therapy, where BCMA loss is rare, four out of six patients who initially responded and then relapsed showed complete loss of GPRC5D expression. Notably, one patient exhibited biallelic deletions at the GPRC5D loci [50]. Additional studies have identified complex GPRC5D deletions and mutations during relapse following anti-GPRC5D bispecific TCE therapy, pointing to genetic alterations that reduce GPRC5D expression [197]. Moreover, Derrien et al. reported a patient with decreased chromatin accessibility at the GPRC5D promoter and distant enhancer regions, suggesting epigenetic silencing [198]. These findings underscore the intricate tumor biology of myeloma and the need for comprehensive treatment strategies to overcome resistance.

GPRC5D-targeted therapies have shown promise, particularly for patients who have previously failed BCMA therapies, offering reduced infection risks [194]. Common side effects include skin and oral issues such as rash and dry mouth, which are generally manageable

with standard care, though taste changes remain a challenge. These therapies are associated with fewer such side effects compared to TCE therapies, possibly due to different tissue distributions and dosing regimens [199]. Some unique side effects of CAR-T cell therapies include dizziness at high doses. Recent studies, including dual-targeted BCMA and GPRC5D therapies, suggest potential for significant improvements in treatment outcomes for MM, highlighting GPRC5D's role in advancing MM treatment strategies [200]. Future clinical trials and novel approaches like dual-targeting constructs and combination therapies are currently being explored, indicating a robust pipeline for enhancing therapeutic efficacy and safety.

CD138 targeted CAR-T cells

CD138 (Syndecan-1), a transmembrane proteoglycan, is primarily expressed on terminally differentiated B cells and is essential for plasma cell survival [201, 202]. However, its expression on other cell types such as epithelial and endothelial cells theoretically limits its utility as a therapeutic target [203]. Despite these challenges, anti-CD138 CAR-T cells have been developed and pre-clinically tested. These cells, as demonstrated by Sun et al., did not affect endothelial or epithelial cells in co-culture experiments [204]. Ongoing clinical and pre-clinical studies, including a U.S. trial (NCT03672318), aim to optimize this therapy. Notably, a novel dual-split CAR construct targeting both CD38 and CD138 antigens showed efficacy in eliminating malignant plasma cells while sparing hematopoietic precursors. Additionally, a phase I trial (NCT01886976) involving a CD138-directed CAR-T cell with a 4-1BB domain in RRMM patients reported manageable side effects and detectable CAR-T cells up to three months post-treatment. Despite CD138 expression in normal tissues, no off-target effects have been reported in ongoing trials, though the limited efficacy of these constructs raises questions about the potential safety of more potent CD138-targeted therapies.

FcRH5 targeted CAR-T cells

Fc receptor-homolog 5 (FcRH5) is predominantly expressed on plasma cells, marking it as a promising target for MM immunotherapy [205]. Its expression is limited primarily to certain B cell subsets and is notably heightened in MM patients with a 1q21 amplification, a known adverse prognostic factor [206]. Cevostamab, a bispecific TCE targeting FcRH5, is currently in early clinical trials and has demonstrated promising efficacy with minimal toxicity [207]. Additionally, preclinical developments include an anti-FcRH5 CAR-T cell therapy that effectively eradicates myeloma cells both in vitro and in vivo [208]. This includes a model of myeloma

resistant to BCMA-targeted therapies. A dual-targeted CAR-T therapy combining anti-BCMA and anti-FcRH5 has also shown potential. While no clinical trials for anti-FcRH5 CAR-T cells are ongoing, their future exploration is anticipated. However, more comprehensive clinical data are required to fully assess the safety and efficacy of FcRH5-directed therapies.

Other potential targets for MM

Several clinical trials have evaluated other targeted CAR-T cell therapies in myeloma with limited success. Trials with anti- κ light chain CAR-T cells aimed at the κ light chain found in many B cell tumors showed no positive responses in myeloma patients [209]. Similarly, trials using anti-NKG2D ligand CAR-T cells, which target widely expressed NKG2D ligands on various tumors, also failed to show effectiveness [210, 211]. Additionally, trials with anti-NY-ESO-1 TCR-engineered T cells post-ASCT indicated some biological activity, but the results were mixed and the effectiveness of the CAR-T cells themselves remains unclear [37, 212]. Preclinical studies have also identified several other potential targets for CAR-T cell therapy in myeloma, including CD44 splice variants [213], CD46 [214], CD56 [215], CD70 [216], CD74 [217], CD229 [218, 219], integrin $\beta 7$ [220], Lewis Y antigen [221], ILT3 [222], SEMA4A [223], CCR10 [224], and Mucin 1 (MUC1) [225].

CAR-NK cells or genetically engineered NK cells

Engineering of natural killer (NK) cells has emerged as a promising cancer therapy, offering an alternative to conventional methods [226–228]. NK cells, which are part of the innate immune system, can be activated without antigen presentation or strict matching of human leukocyte antigens (HLAs), unlike T cells. This allows the development of CAR-NK cells, which are less likely to induce graft-versus-host disease (GVHD), making them suitable for "off-the-shelf" use [229, 230]. CAR-NK cells can be sourced from established NK cell lines like NK92 or from induced pluripotent stem cells (iPSCs), bypassing the need for cells from the actual patient [231, 232]. Additionally, NK cells kill cancer cells by releasing perforin and granzyme, and expressing ligands such as FasL and TRAIL, significantly reducing the risk of CRS often associated with CAR-T cell therapies [233, 234]. NK cells can be derived from various sources, including peripheral and cord blood, as well as iPSCs, allowing for allogeneic use that does not require donor-patient HLA matching. This versatility could potentially lower the costs of CAR cell therapies. CAR-NK therapy is appealing because it is less likely to cause CRS and GVHD and can counteract the tumor's resistance mechanisms [235]. However,

challenges remain, such as lower transduction efficiency and expansion issues, particularly with peripheral blood-derived NK cells. Cord blood-derived NK cells tend to minimize these problems but are relatively immature, which is a drawback [236, 237]. NK92, an IL-2-dependent immortalized cell line derived from a lymphoma patient, requires irradiation before clinical use due to safety concerns, despite the general safety of infusion. The primary advantages of NK92 are its ease of expansion and availability, which reduce both treatment initiation time and costs. However, while NK-92 cell lines are readily manipulable and expandable, they pose safety risks and exhibit poor long-term survival [238, 239]. Enhancing the survival, cytotoxicity, and tumor-targeting of CAR-NK cells are critical areas of ongoing research in improving the effectiveness of CAR-NK cell therapies.

Ren et al. and Cao et al. developed BCMA-specific CAR-NK cells targeting MM, enhancing cytotoxicity and survival in mouse models [240, 241], with ongoing clinical trials (NCT03940833 and NCT05182073) exploring their therapeutic potential. Jiang et al. demonstrated that CD138-specific CAR-NK cells target CD138-positive malignancies, potentially improving remission outcomes post-chemotherapy [242]. Chu et al. advanced SLAMF7-specific CAR-NK cell therapy, showing significant tumor inhibition and survival extension in MM models, indicating its promising treatment prospects [243]. Additionally, studies revealed that NKG2D-CAR NK cells, engineered from autologous NK cells of MM patients, safely enhance antimyeloma activity [244]. Reiser et al. developed the iPSC-derived FT555 CAR-NK cell product targeting GPRC5D and CD38, used alongside daratumumab, providing a scalable, off-the-shelf therapeutic option for broad MM patient access [245]. These innovations highlight significant advances in NK cell therapies for MM, focusing on dual targeting and engineered enhancements to improve efficacy and patient outcomes.

CAR-NK cell therapy, inspired by CAR-T methods, requires sophisticated cell processing facilities and trained personnel. Optimizing CAR properties and NK cell metabolism is key to combating drug-resistant MM. NK cells, with their inherent anti-tumor abilities, are enhanced to improve lifespan and activation for better MM response. CAR-NK targets multiple stable antigens to avoid issues like antigen shedding and off-target effects seen with CAR-T therapies. Additionally, off-the-shelf NK cell therapies are being developed to reduce costs and widen patient access. Unlike T cell therapies, repeated NK cell doses are necessary for a sustained and effective anti-MM response, offering

a promising alternative for improving MM patient outcomes.

Bi- and trispecific immune cell engagers for cell therapy of MM

Bi- and trispecific T cell and NK cell engagers are emerging targeted immunotherapies aimed at enhancing the antitumor response against MM [246–249]. These molecules typically consist of single-chain variable fragments that bind simultaneously to CD3 on T cells and a tumor-associated antigen like BCMA or CD19, commonly overexpressed in MM cells [149, 250]. By forming an immunological synapse between T cells and cancer cells, these engagers facilitate targeted tumor cell killing. Trispecific engagers further enhance this approach by incorporating an additional binding domain, boosting specificity and immune attack potency [251]. NK cell engagers activate NK cells by targeting receptors such as CD16, alongside a tumor-specific antigen, directing NK cell cytotoxicity towards MM cells [252–254]. These dual and triple targeting strategies amplify the immune response and mitigate antigen escape, a common challenge in MM treatment [140, 255, 256]. However, these engagers can induce severe side effects like CRS, necessitating ongoing optimization to balance efficacy with safety [246, 257]. Current clinical trials are promising, indicating potential in achieving sustained responses in MM, particularly in cases resistant to conventional treatments [258]. Integrating these novel engagers with other therapies could enhance outcomes through a robust, precisely targeted immune approach.

As mentioned previously, BCMA is a crucial target in MM treatment due to its role in cell proliferation and survival. It is primarily expressed on malignant and normal plasma cells, but not on hematopoietic stem cells or most non-hematopoietic tissues, making it an ideal target for T cell-redirecting therapies. Elevated levels of soluble BCMA (sBCMA) are associated with disease progression. The FDA has approved several BCMA-targeted therapies, including CAR-T products Abecma and cilta-cel, and the antibody–drug conjugate belantamab mafodotin, which was withdrawn in 2022 after failing a phase III trial [259]. In October 2022, subcutaneous teclistamab was approved for patients with RRMM who had previously failed multiple treatments, marking it the first anti-BCMA×anti-CD3 TCE bispecific antibody (BsAb) to receive approval [260]. Teclistamab showed an ORR of 63% and CR rate of 39.4% in clinical trials (NCT03145181, NCT04557098). Despite a lower response rate compared to some CAR-T treatments, teclistamab offers a safer profile and easier production [261, 262]. Other promising BCMA-targeted BsAbs like elranatamab and linvoseltamab are undergoing FDA

review or clinical trials with favorable preliminary results [263, 264]. Emerging treatments for MM include talquetamab and cevostamab. Talquetamab targets GPRC5D, a novel receptor expressed on MM cells. Cevostamab (RG6160) is an FcRH5×CD3 TCE that binds to a membrane-proximal epitope of FcRH5, promoting efficient synapse formation and MM cell killing. Clinical studies have demonstrated high efficacy for both treatments [265, 266]. Other strategies include targeting CD38 and SLAMF7 with TCE BsAbs and exploring trispecific antibodies (TsAbs) combining multiple targets for enhanced efficacy [246].

It is worth noting that redirecting NK cells to kill tumors is a potential alternative to T cell based therapies, which, though effective, often cause severe side effects like CRS. Clinical responses observed with anti-CD19 CAR-NK cells, without major toxic effects, illustrate the potential of NK cell based immunotherapy [267]. Most NK cell engagers (NKCEs) display an antibody fragment directed against CD16a, similar to the CD3-targeting moiety of TCE [268]. NKCEs like AFM13, a chimeric tandem diabody (TandAb) with anti-CD30 and anti-CD16a domains, have shown potent ADCC and promising results in clinical trials, especially when combined with allogenic NK cells [269]. Advanced NKCEs such as antibody-based NKCE technology and trispecific NKCE therapies platforms incorporate multiple binding domains to enhance NK cell activation and tumor cell killing. For example, the trispecific NKCE (IPH6401/SAR445514) targets BCMA, NKP46, and CD16a, showing potent anti-tumor activity in preclinical studies and ongoing phase I trials [270]. IL-15-based trifunctional NK cell engagers (TriKEs) like GTB-5550 enhance NK cell activation and proliferation, showing promising preclinical results in treating MM [271]. Overall, bi- and trispecific T cell and NK cell engagers represent a significant advancement in MM therapy, offering targeted, potent, and potentially safer alternatives to existing treatments. Ongoing clinical trials and optimization efforts are crucial to fully realizing their therapeutic potential and integrating them into standard MM treatment regimens.

Other adoptive cell therapies for MM

Lymphokine-activated killer (LAK) cells

Lymphokine-activated killer (LAK) cells, primarily derived from NK cells and T-lymphocytes, are activated by interleukin-2 (IL-2) and exhibit potent cytotoxic activity against tumor cells [272, 273]. LAK cells express NK markers such as CD3[−]CD56⁺ and NKG2D, allowing for HLA-independent killing mechanisms [274, 275]. A phase I/II trial assessed low-dose recombinant interleukin-2 (rIL-2) in advanced MM patients who failed standard chemotherapy [53]. Eighteen patients received

subcutaneous rIL-2. Tumor response occurred in 6 of 17 patients: 2 had tumor reduction, and 4 achieved stable disease. Eosinophil counts increased 15-fold, CD4⁺ T cells activated, and CD56⁺ NK cells expanded. The CD4⁺/CD8⁺ ratio normalized, and NK/LAK cell activities enhanced. Endogenous rIL-2 production and soluble rIL-2 receptor levels also increased. In another clinical trial, 16 patients received rIL-2 and LAK cells to reduce relapse rates after autologous bone marrow transplantation (ABMT) [54]. Common side effects included fever, nausea, and rash. Dose-limiting but reversible toxicities were hypotension and thrombocytopenia. Higher rIL-2 doses enhanced NK and LAK cell activity, indicating a strong immunomodulatory effect. These results suggest that rIL-2 and LAK cells warrant further investigation for reducing relapse in advanced hematological malignancies. While low-dose rIL-2 can boost immune function in MM, its efficacy is limited in advanced stages due to tumor-induced immunodeficiency. Future studies should explore the role of rIL-2 in maintaining remission post-chemotherapy. Interestingly, Gottlieb et al. found rIL-2 enhanced cytotoxicity in plasma cell lines and malignant cells from MM patients [276]. Healthy donors' PBMCs showed minimal killing ability, increasing slightly with rIL-2. MM patients' PBMCs induced significant lysis of malignant cells post-rIL-2 exposure. rIL-2-stimulated monocytes released TNF and interferon- γ (IFN γ), reducing malignant cell survival in culture. In vivo, four MM patients received seven rIL-2 courses post-ABMT without serious side effects. rIL-2 increased NK and LAK cell activities and TNF and IFN γ production. These results suggest rIL-2 administration in MM warrants further evaluation, especially for controlling minimal residual disease. However, LAK cell therapy has been replaced by more specific immunotherapies [277, 278].

$\gamma\delta$ T cells from TILs and PBMCs

$\gamma\delta$ T cells, a distinct subset of T cells abundant in mucosal organs, constitute less than 5% of peripheral blood lymphocytes [279–281]. They are non-HLA-restricted cytotoxic cells playing a crucial role in both innate and adaptive immunity by directly recognizing and killing pathogens and activating T and B lymphocytes through cytokine release [282, 283]. $\gamma\delta$ T cells kill cancer cells through direct recognition via TCRs and natural killer cell receptors (NKR). They induce apoptosis using TRAIL, FAS ligand (FASL), and the granule exocytosis pathway, releasing perforin and granzymes. $\gamma\delta$ T cells also mediate ADCC when tumor-specific antibodies are present. They enhance antitumor immunity by producing IFN γ and acting as antigen-presenting cells to activate $\alpha\beta$ T cells. Additionally, they express the 4-1BB ligand (4-1BBL) to stimulate NK cells and

induce antibody class switching in B cells. $\gamma\delta$ T cells produce granulocyte-macrophage colony-stimulating factor (GM-CSF) to regulate dendritic cell (DC) infiltration. Their antitumor activity is further enhanced by IL-2, IL-15, IL-18, and IL-21 [284, 285] (Fig. 4). In MM, $\gamma\delta$ T cells are activated by non-peptide antigens and stress-induced ligands, exhibiting cytotoxic activity by killing MM cells via perforin, granzyme, and death receptor pathways, and recognizing stress-induced ligands such as MICA/B and ULBP1-4 via the NKG2D receptor [286–289]. Additionally, they produce pro-inflammatory cytokines like IFN- γ and TNF- α , enhancing the immune response, and modulate the tumor microenvironment to promote anti-tumor immunity [285]. Therapeutically, $\gamma\delta$ T cells can be expanded ex vivo for adoptive cell therapy and combined with monoclonal antibodies, checkpoint inhibitors, or chemotherapy to boost anti-tumor effects [290]. Challenges include achieving sufficient ex vivo expansion, overcoming the immunosuppressive microenvironment, and ensuring safety [291]. Preclinical and clinical trials are exploring the efficacy and safety of $\gamma\delta$ T cell-based therapies in MM [55, 56, 292]. In hematological malignancies, Wilhelm et al. reported the infusion of allogeneic $\gamma\delta$ T cells from healthy donors in patients with advanced refractory MM who were not eligible for allogeneic transplantation [57]. While CAR- $\gamma\delta$ T cells showed promise, their limited proliferation and diversity led researchers to develop $\alpha\beta$ T cells expressing $\gamma\delta$ TCRs, known as TEGs [291]. These TEGs can target various hematological tumors, exhibiting potent antitumor activity, strong proliferation, and preserved CD4⁺ and CD8⁺ effector functions, leading to tumor eradication in the leukemia patient derived xenograft (PDX) model [293]. A phase I clinical trial (NCT04688853) is currently testing TEG002, an autologous T cell transduced with a specific $\gamma\delta$ TCR, in patients with RRMM. In general, these cells hold significant potential as a therapeutic option, with further research needed to realize their full potential in improving patient outcomes.

Dendritic cell (DC) vaccination

Dendritic cell (DC) vaccines work by inducing and supporting an immune response to eradicate tumor cells. Autologous DCs, when pulsed with peptides or proteins derived from tumor lysates, can stimulate the production of cytotoxic T cells in MM patients [294–296] (Fig. 5). There are four main methods for using DCs as cell-based vaccines against cancer: co-culturing DCs with isolated autologous tumor tissues, co-culturing DCs with synthetic peptides or recombinant proteins of a tumor antigen, transfecting DCs with a specific plasmid to express tumor antigens, and fusing DCs with complete tumor cells using polyethylene glycol [297–299]. These methods

enhance the ability of DC vaccines to stimulate a targeted immune response against MM. Han et al. showed that lentiviral-induced overexpression of calnexin (CNX) in DCs of MM patients enhanced MM-specific CD4 and CD8 T-cell responses, overcoming immune suppression [300]. CNX overexpression did not impact regulatory T cell (Treg) expansion. This suggests that improving antigen processing in DCs can lower the activation threshold of immune effector cells, potentially bypassing Treg-mediated suppression. Currently, the phase I clinical trial (NCT06435910) for this study is also ongoing. Genetically engineering DCs may thus enhance cancer immunotherapy. A randomized phase II trial (NCT02728102) found that combining DC/MM fusion vaccination with lenalidomide did not significantly increase CR rates one year post-transplant [58]. However, it did lead to a notable rise in circulating MM-reactive lymphocytes, suggesting enhanced tumor-specific immunity.

Cytokine-induced killer (CIK) cells

Cytokine-Induced Killer (CIK) cells are a diverse group of effector cells derived from PBMCs and expanded in vitro using IFN- γ , anti-CD3 antibody, and IL-2 [301, 302]. First described over 30 years ago, CIK cells are an innovative cancer immunotherapy strategy. They involve modifying and utilizing autologous or allogeneic CD3⁺CD56[−] T cells and CD3⁺CD56⁺ NK-T cells, which can recognize tumor cells without HLA restriction [303, 304].

CIK cells possess potent antitumor activity due to their combined T cell (CD3⁺) and NK cell (CD56⁺) characteristics [305, 306]. They can be used in various therapeutic approaches (Fig. 6), including: combining with immune checkpoint inhibitors, antibody-mediated interventions to counter tumor ligand shedding, adoptive transfer of CIK cells engineered with CARs, ADCC, tri-specific CIK engagers, dendritic cell-CIK combinations (DC-CIK) and epigenetic inhibitors [307–313]. These mechanisms enable CIK cells to target MM cells through direct cytotoxicity and cytokine release. In the preclinical phase, Pu et al. demonstrated that combining HDAC inhibitors (HDACis) with CIK cells significantly enhances cytotoxicity against MM. This combination shows potential as a promising treatment option for MM patients. Additionally, Poles et al. showed that BCMA-CARs or affinity-optimized CD38-CARs with CIK cells not only spared normal hematopoietic cells but also exhibited a Th1-like cytokine profile, further supporting their therapeutic utility in MM [314].

Clinical trials in China have demonstrated that DC/CIK cells are safe and can induce clinical responses in MM patients, both as a standalone therapy and in combination with chemotherapy and other immunotherapies [315]. However, other clinical trials (NCT00477035,

NCT00185757, NCT00460694) in the world have been completed without relevant clinical effect evaluations being reported. CIK cell therapy is notable for its broad antitumor activity, low risk of graft-versus-host disease (GVHD), and ease of expansion *in vitro*. Interest is growing in understanding the role of CIK cell therapy within the current and future landscape of immuno-oncology [316]. Ongoing research focuses on optimizing expansion protocols, exploring combination therapies, and developing personalized treatments. CIK cells present a promising immunotherapeutic approach for MM, with further research needed to solidify their role in clinical practice.

Conclusion and future perspectives

This manuscript reviews the evolution of cell therapy for MM, highlighting recent advancements and future perspectives. Cell therapies have emerged as transformative

options in MM treatment, demonstrating significant promise, particularly for patients with refractory or relapsed disease. Recent preclinical and clinical studies have underscored the efficacy of CAR-T cells, NK cells, and other immune effector cells. However, notable challenges persist in ensuring the safety and efficacy of these therapies, including CRS, neurotoxicity, and antigen escape, which complicate clinical outcomes.

Further investigation is essential to assess the durability of responses and the long-term safety profiles of these therapies. Each ACT approach for MM offers distinct strengths and limitations. CAR-T therapy, particularly targeting BCMA, currently demonstrates the highest efficacy and durability. BiTEs show significant promise in terms of accessibility and safety, while TCR therapy, NK cell therapy and other therapies are still in exploratory




Fig. 4 Antitumour $\gamma\delta$ T cell functions and their regulation. $\gamma\delta$ T cells recognize and kill tumor cells via their TCRs and NKR, mediating tumor cell killing through TRAIL, FASL, and the granule exocytosis pathway, which involves perforin and granzyme secretion. Additionally, they engage in antibody-dependent cellular cytotoxicity when tumor-specific antibodies are present. $\gamma\delta$ T cells enhance antitumor immune responses by producing IFN γ and acting as antigen-presenting cells, which activate $\alpha\beta$ T cells. They also express the 4-1BBL to stimulate NK cells and induce antibody class switching in B cells, bolstering the humoral response. Moreover, $\gamma\delta$ T cells produce GM-CSF to regulate DC infiltration. The antitumor activity of $\gamma\delta$ T cells is further enhanced by IL-2, IL-15, IL-18, and IL-21. Fc γ RIII, Fc γ receptor III; HLA-DR, human leukocyte antigen-DR; LDL, low-density lipoprotein; MHC, major histocompatibility complex; NKG2D, natural killer group 2D; TRAIL-R, TRAIL receptor. Figure created with BioRender.com

stages but may contribute to a more personalized treatment landscape in the future.

Off-the-shelf CAR-T and NK cell therapies are emerging as promising options for MM, offering advantages over traditional approaches. Their pre-manufactured nature allows for immediate availability, reduced costs, and consistent quality. Initial clinical trials targeting antigens like BCMA have shown high response rates in patients with RRMM. Nevertheless, challenges such as GVHD and antigen escape necessitate careful monitoring and innovative strategies.

Ongoing research aims to enhance the efficacy of these therapies through combination strategies and the identification of new therapeutic targets. Optimizing CAR-T cell design and delivery to minimize adverse effects and enhance persistence is critical. Developing next-generation CAR constructs, dual-targeting CARs, and safety switches is essential. Moreover, integrating cell therapy with other therapeutic modalities—such as immunomodulators, proteasome inhibitors, and monoclonal antibodies—could yield synergistic effects and address resistance mechanisms.

Exploring alternative immune effector cells, such as CAR-NK cells and TCR-engineered T cells, presents further avenues for effective treatment. Establishing robust biomarkers for patient selection and response monitoring is vital for personalizing treatment strategies.

Adoptive cellular immunotherapy has opened new therapeutic avenues for patients with MM, especially those with limited options. While CAR-T cell therapies demonstrate transformative potential, challenges such as manufacturing complexity, toxicities, and immune evasion remain. Emerging strategies, including NK cell therapies, cytokine-induced killer (CIK) cell therapies, and bispecific antibodies, hold promise for overcoming the limitations of existing therapies. Future research should prioritize optimizing these strategies, reducing associated toxicities, and exploring novel targets to achieve sustained and widespread responses. Collaborative efforts among clinicians, researchers, and industry stakeholders will be pivotal in translating these advances from bench to bedside, ultimately leading to more effective and durable treatments for patients with MM.




Fig. 5 Immune activation of DCs in MM. The process begins with isolating DCs from the patient's blood via leukapheresis. These cells are then cultured with specific growth factors to differentiate into immature DCs, which are subsequently matured with stimuli like TNF- α . The mature DCs are loaded with myeloma-specific antigens from sources such as tumor lysates, peptides, or mRNA/DNA encoding myeloma antigens. Once loaded, these antigen-presenting DCs are injected back into the patient, typically intradermally or subcutaneously. The DCs then migrate to germinal centers (like lymph nodes), where they activate naïve T cells, leading to the generation of cytotoxic T lymphocytes (CTLs) that specifically target and kill MM cells. Additionally, helper T cells support the immune response by secreting cytokines. Some activated T cells become memory T cells, offering long-term surveillance against MM recurrence. Figure created with BioRender.com




Fig. 6 Approaches for CIK cell immunotherapy. CIK therapy employs various mechanisms to enhance its efficacy, such as combining with immune checkpoint inhibitors or epigenetic inhibitors, using antibody-mediated intervention to address tumor ligand shedding, and adopting the transfer of CIK cells engineered with CARs. It also includes ADCC, the use of tri-specific CIK engagers, and DC-CIK combinations. These approaches collectively improve the therapeutic potential of CIK cells in targeting and eliminating cancer cells. Figure created with BioRender.com

Abbreviations

MM	Multiple myeloma
ACT	Adoptive cellular immunotherapy
ASCT	Autologous stem cell transplantation
CAR	Chimeric antigen receptor
BCMA	B-cell maturation antigen
NK	Natural killer
TCR	T-cell receptor
MGUS	Monoclonal gammopathy of undetermined significance
TME	Tumor microenvironment
RRMM	Relapsed/refractory multiple myeloma
FDA	The United States Food and Drug Administration
DCs	Dendritic cells
ATILs	Adoptive transfer of tumor-infiltrating lymphocytes
BiCEs	Bispecific immune cell engagers
TriCEs	Trispecific immune cell engagers
LAK	Lymphokine-activated killer
TILs	Tumor-infiltrating lymphocytes
PBMCs	Peripheral blood mononuclear cells
HDM	High-dose melphalan
PFS	Progression-free
mPFS	Median progression-free
OS	Overall survival
mOS	Median overall survival
VTd	Bortezomib, thalidomide, and dexamethasone
VRd	Bortezomib, lenalidomide, and dexamethasone

D-VTd	VTd combined with daratumumab
D-VRd	VRd combined with daratumumab
I-VRd	VRd combined with isatuximab
ASCO	American Society of Clinical Oncology
ESMO	European Society for Medical Oncology
EBMT	European Bone Marrow Transplantation
PI	Proteasome inhibitor
IMiD	Immunomodulatory drug
NDMM	Newly diagnosed multiple myeloma
CR	Complete response
sCR	Stringent complete response
MRD	Minimal residual disease
KRd	Carfilzomib, lenalidomide and dexamethasone
D-KRd	KRd combined with daratumumab
I-KRd	KRd combined with isatuximab
ADCC	Antibody-dependent cellular cytotoxicity
HSC	Hematopoietic stem cells
G-CSF	Granulocyte colony-stimulating factor
MHC	Major histocompatibility complex
pMHC	Peptide-MHC
ITAMs	Immunoreceptor tyrosine-based activation motifs
CTA	Cancer/testis antigen
MAGE	Melanoma antigen gene
scFv	Single-chain variable fragment
APRIL	A proliferation-inducing ligand
BAFF	B-cell activating factor

CRS	Cytokine release syndrome
ICANS	Immune effector cell-associated neurotoxicity syndrome
ORR	Overall response rate
VGPR	Very good partial response
CTX	Cyclophosphamide
FAM	Fludarabine
pt	Per test
mDOR	Median duration of response
DOR	Duration of response
DLTs	Dose-limiting toxicities
SLAMF7	Signaling lymphocytic activation molecule family member 7
ICANS	Immune effector cell-associated neurotoxicity syndrome
GPRC5D	G protein-coupled receptor class C group 5 member D
PIs	Proteasome inhibitors
FcRH5	Fc receptor-homolog 5
TCEs	T-cell engagers
TRUCKS	T cells redirected for universal cytokine-mediated killing
GVHD	Graft-versus-host disease
HLAs	Human leukocyte antigens
iPSCs	Induced pluripotent stem cells
sBCMA	Soluble BCMA
BsAb	Bispecific antibody
TsAbs	Trispecific antibodies
NKCEs	NK cell engagers
TandAb	Tandem diabody
TriKEs	Trifunctional NK cell engagers
IL-2	Interleukin-2
rIL-2	Recombinant interleukin-2
ABMT	Autologous bone marrow transplantation
IFN γ	Interferon- γ
NKRs	Natural killer cell receptors
FASL	FAS ligand
4-1BBL	4-1BB ligand
GM-CSF	Granulocyte-macrophage colony-stimulating factor
PDX	Patient derived xenograft
CNX	Calnexin
Tregs	Regulatory T cells
CTLs	Cytotoxic T lymphocytes
CIK	Cytokine-Induced killer
DC-CIK	Dendritic cell-CIK combinations
HDACis	Histone deacetylase inhibitors
BMMCs	Bone marrow mononuclear cells
MM Id-Ig	Multiple myeloma-specific idiotype immunoglobulins

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40164-024-00576-6>.

Supplementary Material 1.

Acknowledgements

This work was supported by the Open Access Publication Fund of the University of Bonn. The CIO Aachen Bonn Köln Düsseldorf is kindly supported by the Deutsche Krebshilfe. JJP and TL are supported by the China Scholarship Council (CSC) from the Ministry of Education, China.

Author contributions

JJP, TL, AS, LPJ, FW, XBR, IGHS-W and JH contributed to conceive, design and revision of the manuscript sections. JJP wrote the manuscript. JJP and TL designed figures and created Tables. JJP, XBR, IGHS-W and JH supervised the manuscript by providing critical feedbacks and revisions. The authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. Not applicable.

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 11 July 2024 Accepted: 14 October 2024

Published online: 28 October 2024

References

- Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. *JAMA*. 2022;327:464–77.
- Rollig C, Knop S, Bornhauser M. Multiple myeloma. *Lancet*. 2015;385:2197–208.
- Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. *Nat Rev Dis Primers*. 2017;3:17046.
- Garfall AL. New biological therapies for multiple myeloma. *Annu Rev Med*. 2024;75:13–29.
- Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2018;378:241–9.
- Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). *Blood Cancer J*. 2020;10:102.
- Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. *Leukemia*. 2009;23:1691–7.
- Garcia-Ortiz A, Rodriguez-Garcia Y, Encinas J, et al. The role of tumor microenvironment in multiple myeloma development and progression. *Cancers*. 2021;13:217.
- Uckun FM. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. *Cancers*. 2021;13:2018.
- Hervas-Salcedo R, Martin-Antonio B. A journey through the inter-cellular interactions in the bone marrow in multiple myeloma: implications for the next generation of treatments. *Cancers*. 2022;14:3796.
- Pu J, Liu T, Wang X, et al. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives. *Exp Hematol Oncol*. 2024;13:45.
- Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. *J Clin Oncol*. 2019;37:1228–63.
- Soekhojo CY, Chng WJ. Treatment horizon in multiple myeloma. *Eur J Haematol*. 2022;109:425–40.
- Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. *J Clin Oncol*. 2023;41:4416–29.
- Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. *Ann Hematol*. 2023;102:1–11.
- Cengiz Seval G, Beksac M. A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma. *Expert Opin Drug Saf*. 2019;18:563–71.
- Elnair RA, Holstein SA. Evolution of treatment paradigms in newly diagnosed multiple myeloma. *Drugs*. 2021;81:825–40.
- Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. *Blood Cancer J*. 2022;12:47.
- Minnie SA, Hill GR. Immunotherapy of multiple myeloma. *J Clin Invest*. 2020;130:1565–75.

20. Joshua DE, Bryant C, Dix C, Gibson J, Ho J. Biology and therapy of multiple myeloma. *Med J Aust.* 2019;210:375–80.
21. Goldschmidt H, Egerer G, Ho AD. Autologous and allogeneic stem cell transplantation in multiple myeloma. *Bone Marrow Transplant.* 2000;25(Suppl 2):S25–26.
22. Gahrton G, Björkstrand B. Progress in haematopoietic stem cell transplantation for multiple myeloma. *J Intern Med.* 2000;248:185–201.
23. Majolino I, Scime R, Indovina A. Autologous blood stem cell transplantation in hematologic malignancies. *Haematologica.* 1990;75:555–66.
24. Rosenblatt J, Avigan D. Role of immune therapies for myeloma. *J Natl Compr Canc Netw.* 2015;13:1440–7.
25. Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. *Br J Haematol.* 2016;172:685–98.
26. Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. *Nat Rev Clin Oncol.* 2023;20:359–71.
27. Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. *J Hematol Oncol.* 2020;13:125.
28. van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. *Lancet Haematol.* 2021;8:e446–61.
29. Roshandel E, Ghaffari-Nazari H, Mohammadian M, et al. NK cell therapy in relapsed refractory multiple myeloma. *Clin Immunol.* 2023;246: 109168.
30. Kriegsmann K, Kriegsmann M, Cremer M, et al. Cell-based immunotherapy approaches for multiple myeloma. *Br J Cancer.* 2019;120:38–44.
31. Tomaipitina L, Russo E, Bernardini G. NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors. *Mol Aspects Med.* 2021;80: 100968.
32. San Miguel JF, Paiva B, Lasarte JJ. Engineering Anti-myeloma responses using affinity-enhanced TCR-engineered T cells. *Cancer Cell.* 2015;28:281–3.
33. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. *Cancer Discov.* 2018;8:1219–26.
34. Ludwig H, Terpos E, van de Donk N, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. *Lancet Oncol.* 2023;24:e255–69.
35. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. *Nat Rev Clin Oncol.* 2018;15:47–62.
36. Sadek NL, Costa BA, Nath K, Mailankody S. CAR T-Cell therapy for multiple myeloma: a clinical practice-oriented review. *Clin Pharmacol Ther.* 2023;114:1184–95.
37. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. *Nat Med.* 2015;21:914–21.
38. Lin Y, Raju NS, Berdeja JG, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. *Nat Med.* 2023;29:2286–94.
39. Xu J, Wang BY, Yu SH, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. *J Hematol Oncol.* 2024;17:23.
40. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-b-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-Year follow-up. *J Clin Oncol.* 2023;41:1265–74.
41. Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *J Clin Invest.* 2019;129:2210–21.
42. Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. *Blood Adv.* 2020;4:3776–87.
43. Shi X, Yan L, Shang J, et al. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. *Am J Hematol.* 2022;97:537–47.
44. Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. *Lancet Haematol.* 2019;6:e521–9.
45. Shi M, Wang J, Huang H, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. *Nat Commun.* 2024;15:3371.
46. Mei H, Li C, Jiang H, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. *J Hematol Oncol.* 2021;14:161.
47. Tang Y, Yin H, Zhao X, et al. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. *J Exp Clin Cancer Res.* 2022;41:2.
48. Zhang H, Liu M, Xiao X, et al. A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. *Leuk Lymphoma.* 2022;63:1418–27.
49. Li C, Xu J, Luo W, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. *Leukemia.* 2024;38:149–59.
50. Mailankody S, Devlin SM, Landa J, et al. GPRC5D-targeted CAR T cells for myeloma. *N Engl J Med.* 2022;387:1196–206.
51. Bal S, Htut M, Nadeem O, et al. BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): updated results from a phase 1 study. *Blood.* 2023;142:219.
52. Zhang M, Wei G, Zhou L, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. *Lancet Haematol.* 2023;10:e107–16.
53. Peest D, Leo R, Bloche S, et al. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. *Br J Haematol.* 1995;89:328–37.
54. Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. *Blood.* 1991;77:2561–8.
55. Fazzi R, Petrini I, Giuliani N, et al. Phase II trial of maintenance treatment with IL2 and zoledronate in multiple myeloma after bone marrow transplantation: biological and clinical results. *Front Immunol.* 2020;11: 573156.
56. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. *Blood.* 2003;102:200–6.
57. Wilhelm M, Smetak M, Schaefer-Eckart K, et al. Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells. *J Transl Med.* 2014;12:45.
58. Chung DJ, Shah N, Wu J, et al. Randomized phase II trial of dendritic cell/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic stem cell transplantation for multiple myeloma: BMT CTN 1401. *Clin Cancer Res.* 2023;29:4784–96.
59. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. *Lancet.* 2007;370:1209–18.
60. Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA. Multiple myeloma: role of autologous transplantation. *Cancer Treat Rev.* 2020;82: 101929.
61. More S, Corvatta L, Manieri VM, et al. Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go? *Cells.* 2022;11:606.
62. Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple myeloma. *Cancers.* 2021;13:863.
63. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis. *Treat Follow-up Hemasphere.* 2021;5: e528.
64. Soekojo CY, Kumar SK. Stem-cell transplantation in multiple myeloma: how far have we come? *Ther Adv Hematol.* 2019;10:2040620719888111.
65. Kumar S, Baizer L, Callander NS, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. *Blood Cancer J.* 2022;12:98.

66. Holstein SA, Richardson PG, Laubach JP, McCarthy PL. Management of relapsed multiple myeloma after autologous stem cell transplant. *Biol Blood Marrow Transplant*. 2015;21:793–8.
67. Lancman G, Sastow DL, Cho HJ, et al. Bispecific antibodies in multiple myeloma: present and future. *Blood Cancer Discov*. 2021;2:423–33.
68. Lakshman A, Kumar SK. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update. *Am J Hematol*. 2022;97:99–118.
69. Dimopoulos MA, Jakubowiak AJ, McCarthy PL, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. *Blood Cancer J*. 2020;10:17.
70. Snowden JA, Sanchez-Ortega I, Corbacioglu S, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. *Bone Marrow Transplant*. 2022;57:1217–39.
71. Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. *Am J Hematol*. 2022;97(Suppl 1):S3–25.
72. Mo CC, Hartley-Brown MA, Midha S, Richardson PG. Upfront or deferred autologous stem cell transplantation for newly diagnosed multiple myeloma in the era of triplet and quadruplet induction and minimal residual disease/risk-adapted therapy. *Cancers*. 2023;15:5709.
73. Krejci J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. *Blood*. 2016;128:384–94.
74. Gozzetti A, Ciofini S, Simoncelli M, et al. Anti CD38 monoclonal antibodies for multiple myeloma treatment. *Hum Vaccin Immunother*. 2022;18:2052658.
75. Kim K, Phelps MA. Clinical pharmacokinetics and pharmacodynamics of daratumumab. *Clin Pharmacokinet*. 2023;62:789–806.
76. Hill E, Morrison C, Kazandjian D. Daratumumab: a review of current indications and future directions. *Semin Oncol*. 2022;49:48–59.
77. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*. 2019;394:29–38.
78. Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2021;22:1378–90.
79. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. *Blood*. 2020;136:936–45.
80. Voorhees PM, Sborov DW, Laubach J, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. *Lancet Haematol*. 2023;10:e825–37.
81. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2024;390:301–13.
82. Costa LJ, Chhabra S, Medvedova E, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. *Lancet Haematol*. 2023;10:e890–901.
83. Frampton JE. Isatuximab: a review of its use in multiple myeloma. *Target Oncol*. 2021;16:675–86.
84. Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. *Clin Cancer Res*. 2019;25:3176–87.
85. Martin T, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. *Blood Cancer J*. 2023;13:72.
86. Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. *Lancet Oncol*. 2022;23:416–27.
87. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2019;394:2096–107.
88. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet*. 2021;397:2361–71.
89. Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. *Lancet Haematol*. 2022;9:e810–21.
90. Leyboldt LB, Tichy D, Besemer B, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. *J Clin Oncol*. 2024;42:26–37.
91. Hoy SM. Motixafortide: first approval. *Drugs*. 2023;83:1635–43.
92. Lanza F, Marchetti M, Zannetti BA. Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection. *Transfus Apher Sci*. 2023;62: 103830.
93. Swinn T, Butler A. Plexixafor use in New Zealand 2016–2019: an observational study. *Intern Med J*. 2023;53:970–7.
94. Giral S, Stadtmayer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plexixafor (AMD 3100). *Leukemia*. 2009;23:1904–12.
95. Jantunen E, Partanen A, Turunen A, Varmavuori V, Silvennoinen R. Mobilization strategies in myeloma patients intended for autologous hematopoietic cell transplantation. *Transfus Med Hemother*. 2023;50:438–47.
96. Wang J, Tannous BA, Poznansky MC, Chen H. CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent. *Pharmacol Res*. 2020;159: 105010.
97. Zappaterra A, Civettini I, Cafro AM, et al. Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients. *Blood Transfus*. 2024;22:328.
98. Venglar O, Kapustova V, Anilkumar Sithara A, et al. Insight into the mechanism of CD34(+) cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy. *Br J Haematol*. 2024;204:1439–49.
99. Hulin C, Offner F, Moreau P, et al. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. *Haematologica*. 2021;106:2257–60.
100. Chhabra S, Callander N, Watts NL, et al. Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. *Transplant Cell Ther*. 2023;29:174.
101. Kauer J, Freundt EP, Schmitt A, et al. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials. *BMC Cancer*. 2023;23:1132.
102. Mai EK, Goldschmidt H, Miah K, et al. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. *Lancet Haematol*. 2024;11:e101–13.
103. Mai EK, Hielscher T, Bertsch U, et al. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients. *Leukemia*. 2024;38:640–7.
104. Tendeiro Rego R, Morris EC, Lowdell MW. T-cell receptor gene-modified cells: past promises, present methodologies and future challenges. *Cytotherapy*. 2019;21:341–57.
105. Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. *Cell Res*. 2017;27:38–58.
106. James JR. Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand density. *Sci Signal*. 2018;11: eaan1088.

107. Mukhopadhyay H, Cordoba SP, Maini PK, van der Merwe PA, Dushek O. Systems model of T cell receptor proximal signaling reveals emergent ultrasensitivity. *PLoS Comput Biol*. 2013;9:e1003004.
108. Schumacher TN. T-cell-receptor gene therapy. *Nat Rev Immunol*. 2002;2:512–9.
109. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol*. 2013;13:227–42.
110. Ping Y, Liu C, Zhang Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. *Protein Cell*. 2018;9:254–66.
111. Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. *Signal Transduct Target Ther*. 2021;6:412.
112. Schlom J, Hodge JW. The diversity of T-cell co-stimulation in the induction of antitumor immunity. *Immunol Rev*. 1999;170:73–84.
113. Pourakbari R, Hajizadeh F, Parhizkar F, Aghebati-Maleki A, Mansouri S, Aghebati-Maleki L. Co-stimulatory agonists: an insight into the immunotherapy of cancer. *EXCLI J*. 2021;20:1055–85.
114. Ishihara M, Kitano S, Kageyama S, et al. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. *J Immunother Cancer*. 2022;10:e003811.
115. Moeller I, Spagnoli GC, Finke J, Veelen H, Houet L. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naive T-cell subtypes. *Cancer Immunol Immunother*. 2012;61:2079–90.
116. Wang L, Jin N, Schmitt A, et al. T cell-based targeted immunotherapies for patients with multiple myeloma. *Int J Cancer*. 2015;136:1751–68.
117. Wachsmann TLA, Meeuwssen MH, Remst DFG, et al. Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma. *Blood Adv*. 2023;7:6178–83.
118. Mastaglio S, Genovese P, Magnani Z, et al. NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. *Blood*. 2017;130:606–18.
119. Schubert PC, Jakka G, Jensen SM, et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. *Gene Ther*. 2013;20:386–95.
120. Atanackovic D, Hildebrandt Y, Jadczyk A, et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. *Haematologica*. 2010;95:785–93.
121. Jungbluth AA, Ely S, DiLiberto M, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. *Blood*. 2005;106:167–74.
122. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. *Leukemia*. 2020;34:985–1005.
123. Yang J, Zhou W, Li D, Niu T, Wang W. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. *Cancer Lett*. 2023;553:215949.
124. Bezverbnaya K, Moogk D, Cummings D, et al. Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. *Cytotherapy*. 2021;23:820–32.
125. Raza A, Merhi M, Inchakalody VP, et al. Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. *J Transl Med*. 2020;18:140.
126. Thomas R, Al-Khadairi G, Roelands J, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. *Front Immunol*. 2018;9:947.
127. Zhou H, Ma Y, Liu F, et al. Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment. *Front Immunol*. 2023;14:1255799.
128. Park TS, Groh EM, Patel K, Kerkar SP, Lee CC, Rosenberg SA. Expression of MAGE-A and NY-ESO-1 in primary and metastatic cancers. *J Immunother*. 2016;39:1–7.
129. Fujiwara S, Wada H, Kawada J, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. *Br J Cancer*. 2013;108:1119–25.
130. Ishihara M, Kageyama S, Miyahara Y, et al. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. *BMC Cancer*. 2020;20:606.
131. Goydos JS, Patel M, Shih W. NY-ESO-1 and Ctp11 expression may correlate with stage of progression in melanoma. *J Surg Res*. 2001;98:76–80.
132. van Rhee F, Szmania SM, Zhan F, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. *Blood*. 2005;105:3939–44.
133. Julve M, Kennedy O, Frampton AE, Bagwan I, Lythgoe MP. Gene of the month: cancer testis antigen gene 1b (NY-ESO-1). *J Clin Pathol*. 2023;77:1–7.
134. Chinnasamy N, Wargo JA, Yu Z, et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. *J Immunol*. 2011;186:685–96.
135. Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice. *Immunotherapy*. 2015;7:683–704.
136. Schafer P, Paraschiakos T, Windhorst S. Oncogenic activity and cellular functionality of melanoma associated antigen A3. *Biochem Pharmacol*. 2021;192:114700.
137. Linette GP, Stadtmayer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. *Blood*. 2013;122:863–71.
138. Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. *J Exp Clin Cancer Res*. 2022;41:119.
139. Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. *Br J Cancer*. 2019;120:26–37.
140. Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. *CA Cancer J Clin*. 2023;73:275–85.
141. Manier S, Ingegnere T, Escure G, et al. Current state and next-generation CAR-T cells in multiple myeloma. *Blood Rev*. 2022;54:100929.
142. Day ES, Cachero TG, Qian F, et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. *Biochemistry*. 2005;44:1919–31.
143. Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. *Blood*. 2016;127:3225–36.
144. Mulazzani M, Huber M, Borchard S, et al. APRIL and BAFF: novel biomarkers for central nervous system lymphoma. *J Hematol Oncol*. 2019;12:102.
145. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. *Cancer Res*. 2006;66:6675–82.
146. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. *Clin Cancer Res*. 2013;19:2048–60.
147. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. *Blood*. 2010;115:3541–52.
148. He C, Zhang M, Liu L, et al. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF. *Acta Biomater*. 2022;143:406–17.
149. Ravi G, Costa LJ. Bispecific T-cell engagers for treatment of multiple myeloma. *Am J Hematol*. 2023;98(Suppl 2):S13–21.
150. Mishra AK, Gupta A, Dagar G, et al. CAR-T-Cell therapy in multiple myeloma: B-Cell Maturation Antigen (BCMA) and beyond. *Vaccines*. 2023;11:1721.
151. Harush O, Asherie N, Kfir-Erenfeld S, et al. Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. *Haematologica*. 2022;107:2395–407.
152. Lin L, Cho SF, Xing L, et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. *Leukemia*. 2021;35:752–63.
153. Perez-Amill L, Sune G, Antonana-Vildosola A, et al. Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. *Haematologica*. 2021;106:173–84.
154. Sommer C, Boldajipour B, Kuo TC, et al. Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma. *Mol Ther*. 2019;27:1126–38.
155. Lin RJ, Sutton J, Bentley T, et al. Constitutive Turbodomains enhance expansion and antitumor activity of allogeneic BCMA CAR T cells in preclinical models. *Sci Adv*. 2023;9:ead8694.
156. Buonato JM, Edwards JP, Zaritskaya L, et al. Preclinical efficacy of BCMA-directed CAR T cells incorporating a novel D domain antigen recognition domain. *Mol Cancer Ther*. 2022;21:1171–83.

157. Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. *J Allergy Clin Immunol*. 2020;146:940–8.
158. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. *Nat Rev Immunol*. 2022;22:85–96.
159. Rana PS, Murphy EV, Kort J, Driscoll JJ. Road testing new CAR design strategies in multiple myeloma. *Front Immunol*. 2022;13:957157.
160. Larson RC, Kann MC, Graham C, et al. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. *Nat Commun*. 2023;14:7509.
161. Tan J, Jia Y, Zhou M, et al. Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. *J Hematol Oncol*. 2022;15:39.
162. Rujirachaivej P, Siriboonpiputtana T, Luangwattananun P, et al. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma. *Clin Exp Med*. 2024;24:90.
163. Anderson LD Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. *Future Oncol*. 2022;18:277–89.
164. Reyes KR, Huang CY, Lo M, et al. Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma. *Transplant Cell Ther*. 2023;29:350–5.
165. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. *Exp Hematol Oncol*. 2012;1:36.
166. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. *Immunol Lett*. 2017;183:86–95.
167. Del Nagro CJ, Otero DC, Anzelon AN, Omori SA, Kolla RV, Rickert RC. CD19 function in central and peripheral B-cell development. *Immunol Res*. 2005;31:119–31.
168. Hasegawa M, Fujimoto M, Poe JC, Steeber DA, Tedder TF. CD19 can regulate B lymphocyte signal transduction independent of complement activation. *J Immunol*. 2001;167:3190–200.
169. Sadelain M. CAR therapy: the CD19 paradigm. *J Clin Invest*. 2015;125:3392–400.
170. Boardman AP, Salles G. CAR T-cell therapy in large B cell lymphoma. *Hematol Oncol*. 2023;41(Suppl 1):112–8.
171. Kang L, Zhang J, Li M, et al. Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. *Biomark Res*. 2020;8:14.
172. van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. *Blood*. 2018;131:13–29.
173. Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma. *Cancer*. 2019;125:2364–82.
174. Bonello F, D'Agostino M, Moscvin M, Cerrato C, Boccadoro M, Gay F. CD38 as an immunotherapeutic target in multiple myeloma. *Expert Opin Biol Ther*. 2018;18:1209–21.
175. Wu HT, Zhao XY. Regulation of CD38 on multiple myeloma And NK cells by monoclonal antibodies. *Int J Biol Sci*. 2022;18:1974–88.
176. Frerichs KA, Nagy NA, Lindenbergh PL, et al. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. *Expert Rev Clin Immunol*. 2018;14:197–206.
177. Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: a target for immunotherapeutic approaches in multiple myeloma. *Front Immunol*. 2018;9:2722.
178. Zannetti BA, Faini AC, Massari E, et al. Novel insights in anti-CD38 therapy based on CD38-receptor expression and function: the multiple myeloma model. *Cells*. 2020;9:2666.
179. Mihara K, Bhattacharyya J, Kitanaka A, et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. *Leukemia*. 2012;26:365–7.
180. Drent E, Groen RW, Noort WA, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. *Haematologica*. 2016;101:616–25.
181. An N, Hou YN, Zhang QX, et al. Anti-multiple myeloma activity of nanobody-based anti-CD38 chimeric antigen receptor T cells. *Mol Pharm*. 2018;15:4577–88.
182. Glisovic-Aplenc T, Diorio C, Chukinas JA, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. *Blood Adv*. 2023;7:4418–30.
183. Partida-Sanchez S, Cockayne DA, Monard S, et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. *Nat Med*. 2001;7:1209–16.
184. Malaer JD, Mathew PA. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. *Am J Cancer Res*. 2017;7:1637–41.
185. Boudreaault JS, Touzeau C, Moreau P. The role of SLAMF7 in multiple myeloma: impact on therapy. *Expert Rev Clin Immunol*. 2017;13:67–75.
186. Wang Y, Sanchez L, Siegel DS, Wang ML. Elotuzumab for the treatment of multiple myeloma. *J Hematol Oncol*. 2016;9:55.
187. Elotuzumab MA. First global approval. *Drugs*. 2016;76:397–403.
188. Gogishvili T, Danhof S, Prommersberger S, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. *Blood*. 2017;130:2838–47.
189. Roders N, Nakid-Cordero C, Raineri F, et al. Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with Independent signaling demonstrate preclinical efficacy and safety in multiple myeloma. *Cancer Immunol Res*. 2024;12:478–90.
190. O'Neal J, Ritchey JK, Cooper ML, et al. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. *Leukemia*. 2022;36:1625–34.
191. Rodriguez-Otero P, van de Donk N, Pillarisetti K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. *Blood Cancer J*. 2024;14:24.
192. Nath K, Costa BA, Mailankody S. GPRC5D as a novel immunotherapeutic target in multiple myeloma. *Nat Rev Clin Oncol*. 2023;20:281–2.
193. Atamaniuk J, Gleiss A, Porpacz E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. *Eur J Clin Invest*. 2012;42:953–60.
194. Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. *Sci Transl Med*. 2019;11: eaau7746.
195. Fernandez de Larrea C, Staehr M, Lopez AV, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. *Blood Cancer Discov*. 2020;1:146–54.
196. Simon S, Riddell SR. Dual targeting with CAR T cells to limit antigen escape in multiple myeloma. *Blood Cancer Discov*. 2020;1:130–3.
197. Mi X, Penson A, Abdel-Wahab O, Mailankody S. Genetic basis of relapse after GPRC5D-targeted CAR T cells. *N Engl J Med*. 2023;389:1435–7.
198. Derrien J, Gastineau S, Frigout A, et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. *Nat Cancer*. 2023;4:1536–43.
199. Zhou X, Yang Y, Hu X, et al. Identification of LPAR1/LPAR5 as novel GPCR partners of GPRC5D for the efficient CAR-T therapy of multiple myeloma. *Blood*. 2023;142:4679.
200. Hou J, Li Y, Lin Q. Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting. *Exp Hematol Oncol*. 2023;12:74.
201. McCarron MJ, Park PW, Fooksman DR. CD138 mediates selection of mature plasma cells by regulating their survival. *Blood*. 2017;129:2749–59.
202. Couchman JR. Syndecan-1 (CD138), carcinomas and EMT. *Int J Mol Sci*. 2021;22:4227.
203. Palaiologou M, Delladetsima I, Tiniakos D. CD138 (syndecan-1) expression in health and disease. *Histol Histopathol*. 2014;29:177–89.
204. Sun C, Mahendravada A, Ballard B, et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. *Oncotarget*. 2019;10:2369–83.
205. Li J, Stagg NJ, Johnston J, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FCRH5/CD3 and is a requirement for myeloma cell killing. *Cancer Cell*. 2017;31:383–95.
206. Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. *Blood Cancer J*. 2021;11:83.

207. Zhao J, Ren Q, Liu X, Guo X, Song Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. *J Hematol Oncol*. 2023;16:92.
208. Jiang D, Huang H, Qin H, et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. *Nat Commun*. 2023;14:3642.
209. Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. *J Clin Invest*. 2016;126:2588–96.
210. Baumeister SH, Murad J, Werner L, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. *Cancer Immunol Res*. 2019;7:100–12.
211. Sallman DA, Kerre T, Havelange V, et al. CYAD-01, an autologous NKG2D-based CAR-T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. *Lancet Haematol*. 2023;10:e191–202.
212. Stadtmayer EA, Faltg TH, Lowther DE, et al. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. *Blood Adv*. 2019;3:2022–34.
213. Casucci M, Nicolis di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. *Blood*. 2013;122:3461–72.
214. Sherbenou DW, Aftab BT, Su Y, et al. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. *J Clin Invest*. 2016;126:4640–53.
215. Cottini F, Rodriguez J, Hughes T, et al. Redefining CD56 as a biomarker and therapeutic target in multiple myeloma. *Mol Cancer Res*. 2022;20:1083–95.
216. Shaffer DR, Savoldo B, Yi Z, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. *Blood*. 2011;117:4304–14.
217. Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. *Clin Cancer Res*. 2004;10:6606–11.
218. Atanackovic D, Panse J, Hildebrandt Y, et al. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. *Haematologica*. 2011;96:1512–20.
219. Radhakrishnan SV, Luetkens T, Scherer SD, et al. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. *Nat Commun*. 2020;11:798.
220. Hosen N, Matsunaga Y, Hasegawa K, et al. The activated conformation of integrin beta(7) is a novel multiple myeloma-specific target for CAR T cell therapy. *Nat Med*. 2017;23:1436–43.
221. Peinert S, Prince HM, Guru PM, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. *Gene Ther*. 2010;17:678–86.
222. Di Meo F, Iyer A, Akama K, et al. A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. *Cell Rep Med*. 2023;4: 101110.
223. Anderson GSF, Ballester-Beltran J, Giotopoulos G, et al. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. *Blood*. 2022;139:2471–82.
224. Ferguson ID, Patino-Escobar B, Tuomivaara ST, et al. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. *Nat Commun*. 2022;13:4121.
225. Yin L, Tagde A, Gali R, et al. MUC1-C is a target in lenalidomide resistant multiple myeloma. *Br J Haematol*. 2017;178:914–26.
226. Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. *J Hematol Oncol*. 2021;14:73.
227. Lamers-Kok N, Panella D, Georgoudaki AM, et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. *J Hematol Oncol*. 2022;15:164.
228. Laskowski TJ, Biederstadt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. *Nat Rev Cancer*. 2022;22:557–75.
229. Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. *EBioMedicine*. 2020;59: 102975.
230. Heipertz EL, Zynda ER, Stav-Noraas TE, et al. Current perspectives on “off-the-shelf” allogeneic NK and CAR-NK cell therapies. *Front Immunol*. 2021;12: 732135.
231. Li Y, Hermanson DL, Moriarty BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. *Cell Stem Cell*. 2018;23(181–192): e185.
232. Lin X, Sun Y, Dong X, Liu Z, Sugimura R, Xie G. iPSC-derived CAR-NK cells for cancer immunotherapy. *Biomed Pharmacother*. 2023;165: 115123.
233. Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. *Biomark Res*. 2022;10:12.
234. Ebrahimiyan H, Tamimi A, Shokoochian B, et al. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. *Int Immunopharmacol*. 2022;106: 108587.
235. Valeri A, Garcia-Ortiz A, Castellano E, et al. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. *Front Immunol*. 2022;13: 953849.
236. Wang L, Dou M, Ma Q, Yao R, Liu J. Chimeric antigen receptor (CAR)-modified NK cells against cancer: opportunities and challenges. *Int Immunopharmacol*. 2019;74: 105695.
237. Maalej KM, Merhi M, Inchakalody VP, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. *Mol Cancer*. 2023;22:20.
238. Klingemann H. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. *Cytotherapy*. 2023;25:451–7.
239. Maddineni S, Silberstein JL, Sunwoo JB. Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. *J Immunother Cancer*. 2022;10: e004693.
240. Ren Q, Zu Y, Su H, et al. Single VHH-directed BCMA CAR-NK cells for multiple myeloma. *Exp Hematol Oncol*. 2023;12:98.
241. Cao Z, Yang C, Wang Y, et al. Allogeneic CAR-NK cell therapy targeting both BCMA and GPRC5D for the treatment of multiple myeloma. *Blood*. 2022;140:7378–7378.
242. Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. *Mol Oncol*. 2014;8:297–310.
243. Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. *Leukemia*. 2014;28:917–27.
244. Leivas A, Valeri A, Cordoba L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. *Blood Cancer J*. 2021;11:146.
245. Reiser J, Chan SR, Mathavan K, et al. FT555: off-the-shelf CAR-NK cell therapy co-targeting GPRC5D and CD38 for the treatment of multiple myeloma. *Blood*. 2022;140:4560–1.
246. Tapia-Galisteo A, Alvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. *J Hematol Oncol*. 2023;16:83.
247. Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. *Nat Rev Clin Oncol*. 2020;17:418–34.
248. Zhou S, Liu M, Ren F, Meng X, Yu J. The landscape of bispecific T cell engager in cancer treatment. *Biomark Res*. 2021;9:38.
249. Tapia-Galisteo A, Compte M, Alvarez-Vallina L, Sanz L. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. *Theranostics*. 2023;13:1028–41.
250. Letouze E, Moreau P, Munshi N, Samur M, Minvielle S, Touzeau C. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. *Blood Adv*. 2024;8:2952–9.
251. Yao Y, Hu Y, Wang F. Trispecific antibodies for cancer immunotherapy. *Immunology*. 2023;169:389–99.
252. Giang KA, Boxaspen T, Diao Y, et al. Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells. *N Biotechnol*. 2023;77:139–48.
253. Li W, Zhang B, Cao W, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing. *Exp Hematol Oncol*. 2023;12:44.
254. Kakiuchi-Kiyota S, Ross T, Wallweber HA, et al. A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma. *Leukemia*. 2022;36:1006–14.
255. Wang C, Wang W, Wang M, et al. Different evasion strategies in multiple myeloma. *Front Immunol*. 2024;15:1346211.

256. Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. *Cancer*. 2020;126:3192–201.
257. Khattak ZE, Hashmi H, Khan SI, et al. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature. *Ann Hematol*. 2021;100:2155–72.
258. Minakata D, Fujiwara SI, Yokoyama D, et al. Relapsed and refractory multiple myeloma: a systematic review and network meta-analysis of the efficacy of novel therapies. *Br J Haematol*. 2023;200:694–703.
259. Belantamab Mafodotin. LiverTox: Clinical and research information on drug-induced liver injury. Bethesda (MD); 2012.
260. Firestone R, Lesokhin AM, Usmani SZ. An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma. *Blood Cancer Discov*. 2023;4:433–6.
261. Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. *Lancet*. 2021;398:665–74.
262. Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. *N Engl J Med*. 2022;387:495–505.
263. Bahlis NJ, Tomasson MH, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma Naïve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study. *Blood*. 2022;140:391–3.
264. Panowski SH, Kuo T, Chen A, et al. Preclinical evaluation of a potent anti-BCMA CD3 bispecific molecule for the treatment of multiple myeloma. *Blood*. 2016;128:383.
265. Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. *Blood Adv*. 2021;5:2196–215.
266. Lesokhin AM, Richter J, Trudel S, et al. Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed/refractory multiple myeloma: early experience from a phase I study. *Blood*. 2022;140:4415–7.
267. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. *N Engl J Med*. 2020;382:545–53.
268. Pinto S, Pahl J, Schottelius A, Carter PJ, Koch J. Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. *Trends Immunol*. 2022;43:932–46.
269. Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. *J Hematol Oncol*. 2015;8:96.
270. Tang A, Gauthier L, Beninga J, et al. The novel trifunctional anti-BCMA NK cell engager SAR514 has potent in-vitro and in-vivo anti-myeloma effect through dual NK cell engagement. *Blood*. 2022;140:9985–6.
271. Miller JS, Zorko N, Merino A, et al. 755P B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells. *Ann Oncol*. 2022;33:S889.
272. Lindemann A, Herrmann F, Oster W, Mertelsmann R. Lymphokine activated killer cells. *Blut*. 1989;59:375–84.
273. Richards JM. Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells. *Blood Rev*. 1989;3:110–9.
274. Morris DG, Pross HF. Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker. *J Exp Med*. 1989;169:717–36.
275. Lobo PI, Chang MY, Mellins E. Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytotoxicity. *Immunology*. 1996;88:625–9.
276. Gottlieb DJ, Prentice HG, Mehta AB, et al. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. *Br J Haematol*. 1990;75:499–505.
277. Paucek RD, Baltimore D, Li G. The cellular immunotherapy revolution: arming the immune system for precision therapy. *Trends Immunol*. 2019;40:292–309.
278. Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. *Nature*. 2023;614:635–48.
279. Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. *Signal Transduct Target Ther*. 2023;8:235.
280. Kabelitz D, Peters C, Wesch D, Oberg HH. Regulatory functions of gamma-delta T cells. *Int Immunopharmacol*. 2013;16:382–7.
281. Vroom TM, Scholte G, Ossendorp F, Borst J. Tissue distribution of human gamma delta T cells: no evidence for general epithelial tropism. *J Clin Pathol*. 1991;44:1012–7.
282. Mensurado S, Blanco-Dominguez R, Silva-Santos B. The emerging roles of gamma-delta T cells in cancer immunotherapy. *Nat Rev Clin Oncol*. 2023;20:178–91.
283. Dong C. Cytokine regulation and function in T cells. *Annu Rev Immunol*. 2021;39:51–76.
284. Silva-Santos B, Mensurado S, Coffelt SB. gamma-delta T cells: pleiotropic immune effectors with therapeutic potential in cancer. *Nat Rev Cancer*. 2019;19:392–404.
285. Hu Y, Hu Q, Li Y, et al. gamma-delta T cells: origin and fate, subsets, diseases and immunotherapy. *Signal Transduct Target Ther*. 2023;8:434.
286. Rimailho L, Faria C, Domagala M, Laurent C, Bezombes C, Poupot M. gamma-delta T cells in immunotherapies for B-cell malignancies. *Front Immunol*. 2023;14:1200003.
287. Caccamo N, La Mendola C, Orlando V, et al. Differentiation, phenotype, and function of interleukin-17-producing human Vgamma-9Vdelta2 T cells. *Blood*. 2011;118:129–38.
288. Wu YL, Ding YP, Tanaka Y, et al. gamma-delta T cells and their potential for immunotherapy. *Int J Biol Sci*. 2014;10:119–35.
289. Obeidy P, Sharland AF. NKG2D and its ligands. *Int J Biochem Cell Biol*. 2009;41:2364–7.
290. Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. Cancer immunotherapy with gamma-delta T cells: many paths ahead of us. *Cell Mol Immunol*. 2020;17:925–39.
291. Sebestyen Z, Prinz I, Dechanet-Merville J, Silva-Santos B, Kuball J. Translating gamma-delta (gamma-delta) T cells and their receptors into cancer cell therapies. *Nat Rev Drug Discov*. 2020;19:169–84.
292. de Weertdt I, Lameris R, Scheffer GL, et al. A Bispecific antibody antagonizes prosurvival CD40 signaling and promotes Vgamma9Vdelta2 T cell-mediated antitumor responses in human B-cell malignancies. *Cancer Immunol Res*. 2021;9:50–61.
293. Marcu-Malina V, Heijhuysen S, van Buuren M, et al. Redirecting alphabeta T cells against cancer cells by transfer of a broadly tumor-reactive gamma-delta T-cell receptor. *Blood*. 2011;118:50–9.
294. Verheye E, Bravo Melgar J, Deschoemaeker S, et al. Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions. *Int J Mol Sci*. 2022;23:904.
295. Allegra A, Penna G, Innano V, et al. Vaccination of multiple myeloma: Current strategies and future prospects. *Crit Rev Oncol Hematol*. 2015;96:339–54.
296. Weinstock M, Rosenblatt J, Avigan D. Dendritic cell therapies for hematologic malignancies. *Mol Ther Methods Clin Dev*. 2017;5:66–75.
297. Cancer vaccine—Antigenics. *BioDrugs*. 2002;16:72–74.
298. Mumper RJ, Ledebur HC Jr. Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization. *Mol Biotechnol*. 2001;19:79–95.
299. Koida S. Dendritic-tumor fusion cell-based cancer vaccines. *Int J Mol Sci*. 2016;17:828.
300. Han S, Wang B, Cotter MJ, et al. Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. *Mol Ther*. 2008;16:269–79.
301. Introna M. CIK as therapeutic agents against tumors. *J Autoimmun*. 2017;85:32–44.
302. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. *J Transl Med*. 2013;11:83.
303. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. *J Exp Med*. 1991;174:139–49.
304. Mata-Molanes JJ, Sureda Gonzalez M, Valenzuela Jimenez B, Martinez Navarro EM, Brugarolas MA. Cancer immunotherapy with cytokine-induced killer cells. *Target Oncol*. 2017;12:289–99.
305. Introna M, Golay J, Rambaldi A. Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms. *Immunol Lett*. 2013;155:27–30.

306. Meng Y, Yu Z, Wu Y, et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: from preparation and testing to clinical application. *Hum Vaccin Immunother*. 2017;13:1–9.
307. Poh SL, Linn YC. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. *Cancer Immunol Immunother*. 2016;65:525–36.
308. Ferrari de Andrade L, Kumar S, Luoma AM, et al. Inhibition of MICA and MICB shedding elicits NK-Cell-mediated immunity against tumors resistant to cytotoxic T cells. *Cancer Immunol Res*. 2020;8:769–80.
309. Biondi M, Tettamanti S, Galimberti S, et al. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden. *Blood*. 2023;141:2587–98.
310. Dalla Pietra A, Cappuzzello E, Palmerini P, et al. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. *J Immunother Cancer*. 2021;9: e002475.
311. Zhang Y, Wu X, Sharma A, et al. Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma. *Front Immunol*. 2022;13: 925633.
312. Wang S, Wang X, Zhou X, Lyster HK, Morse MA, Ren J. DC-CIK as a widely applicable cancer immunotherapy. *Expert Opin Biol Ther*. 2020;20:601–7.
313. Pu J, Sharma A, Liu T, Hou J, Schmidt-Wolf IG. Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway. *Clin Transl Immunol*. 2024;13: e1500.
314. Poels R, Drent E, Lameris R, et al. Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma. *Int J Mol Sci*. 2021;22:1096.
315. Wang Y, Lv B, Li K, Zhang A, Liu H. Adjuvant immunotherapy of dendritic cells and cytokine-induced killer cells is safe and enhances chemotherapy efficacy for multiple myeloma in China: a meta-analysis of clinical trials. *Drug Des Devel Ther*. 2017;11:3245–56.
316. Sharma A, Schmidt-Wolf IG. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. *J Exp Clin Cancer Res*. 2021;40:388.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.